Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health

Sukrit Srivastava^{a,b}, Ajay Kumar Saxena^b, Michael Kolbe^{*c,d},

a Infection Biology Group, Indian Foundation for Fundamental Research, RaeBareilly 229001, India

b Molecular Medicine Lab., School of Life Science, Jawaharlal Nehru University, 110067 New Delhi, India.

c Department for Structural Infection Biology, Centre for Structural Systems Biology (CSSB) & Helmholtz-Centre for Infection Research, Notkestraße 85, 22607 Hamburg, Germany.

d Faculty of Mathematics, Informatics and Natural Sciences, University of Hamburg, Rothenbaumchaussee 19, 20148 Hamburg, Germany.

*Correspondence should be addressed to S.S. (srivastava.sukrit@iffr.in; srivastav.sukrit@gmail.com); and M.K. (Michael.Kolbe@helmholtz-hzi.de)

ABSTRACT

Nipah virus (NiV) is an emerging zoonotic virus responsible to cause several serious outbreaks in South Asian region with high mortality rate of 40 to 90% since 2001. NiV infection causes lethal encephalitis and respiratory disease with the symptom of endothelial cell-cell fusion. No specific vaccine has yet been reported against NiV infection. Recently, some Multi-Epitope Vaccines (MEV) has been proposed but they involve limited number of epitopes which further limits the potential of vaccine. To address the urgent need for a specific and effective vaccine against NiV infection, in the present study, we have design two multi-epitope vaccines (MEVs) composed of 33 Cytotoxic T lymphocyte (CTL) epitopes and 38 Helper T lymphocyte (HTL) epitopes. Both the MEVs carry

potential B cell linear epitope overlapping regions, B cell discontinuous epitopes as well as IFN- γ inducing epitopes. Hence the designed MEVs carry potential to elicit cell-mediated as well as humoral immune response. Selected CTL and HTL epitopes were validated for their stable molecular interactions with HLA class I and II alleles as well as in case of CTL epitopes, with human transporter associated with antigen processing (TAP). Human β -defensin 2 and β -defensin 3 were used as adjuvants to enhance the immune response of both the MEVs. The molecular dynamics simulation study of MEVs-TLR3(ECD) (Toll-Like Receptor 3 Ectodomain) complex indicated stable molecular interaction. Further, the codon optimized cDNA of both the MEVs has shown high expression potential in the mammalian host cell line (Human). Hence for further studies, both the design of CTL and HTL MEVs could be cloned, expressed and tried for *in-vivo* validations (animal trails) as potential vaccine candidates against NiV infection.

Key words: Nipah virus (NiV), Human Transporter associated with antigen processing (TAP), Toll-Like Receptor 3 (TLR-3), Epitope, Immunoinformatics, Molecular Docking, Molecular Dynamics (MD) simulation, Multi-epitope Vaccine (MEV)

INTRODUCTION

Nipah virus (NiV) is an emerging zoonotic virus of the genus Henipavirus of the Paramyxoviridae family [1]. NiV infection causes fatal encephalitis and respiratory disease with a particular symptom of endothelial cell-cell fusion [2].

The first NiV infection to human was first reported in Malaysia in 1998. Later NiV outbreak was reported from Meherpur, Bangladesh in 2001. In the Malaysia NiV infection, the transmission was primarily due being in contact of pigs, whereas in later outbreaks of Bangladesh and India the transmission was associated with contaminated date palm sap and human-to-human contact [3]. Bats are identified as the main reservoir for the NiV and they are responsible for the transmission of the infection to both humans and animals [4]. After 2001 NiV outbreak has been reported from different district of Bangladesh almost every year (2003-05, 2007-12). Till March 31, 2012, a total of 209 confirmed cases of NiV infections were reported out of which 161 people died resulting in the mortality rate as high as 77%. After several outbreaks in Bangladesh, in total three NiV outbreaks have also been reported from India. Two of them occurred in the state of West Bengal in 2001 and 2007 [5]. The most recent NiV outbreak was reported from the Kerala state of India during the period of May to June-2018. The Kerala outbreak claimed 17 lives leaving only two survivors out of 19 confirmed cases [6]. Till present, there has been no specific vaccine reported against NiV infection, and the pathogenesis mechanism of NiV to human cells is largely unknown. Hence, an immune-informatics approach investigating the potential of different NiV proteins for vaccine design would be an important and essential step forward for vaccine development.

NiV infection of human cells involves several protein-protein interactions and protein cluster formation on the host cell surface. Essential proteins involved in NiV pathogenesis include C protein, Fusion glycoproteins (F), Glycoproteins

(G), Matrix proteins (M), Nucleocapsid protein, Phosphoprotein, Polymerase, V protein and the W protein [7-21]. The C protein regulates the early host pro-inflammatory response as well as the pathogen virulence thus providing a conducive environment for a successful NiV infection [7]. The attachment glycoprotein (G), the fusion protein (F) and the matrix protein (M) together form a cluster on the human cell membrane facilitating virus particle assembly and pathogenesis [8-12]. The G and F proteins of NiV have been shown to be immunogenic by inducing protective immune responses in hamsters [22, 23]. The NiV matrix protein is observed to play a central role in virus particle formation and is essentially required for viral budding from the infected human cells [13-15]. The NiV Polymerase is responsible for the initiation of RNA synthesis, primer extension, and transition to elongation mode and hence the enzyme facilitates viral pathogenesis and survival in host cells [16]. The phosphoprotein and the glycoprotein of NiV are crucially involved in the regulation of viral replication [17, 18] while the V protein of NiV is responsible for the host interferon (IFN) signalling evasion during pathogenesis [19, 20]. Interestingly, the identical N-terminal region of the pathogen's V and W protein is sufficient to exert the IFN-antagonist activity [21]. Hence, all the nine above mentioned NiV proteins are crucial in different ways for viral pathogenesis and are important drug and vaccine candidates.

The Nipah virus is a zoonotic RNA virus and it infects human respiratory epithelium cells as well as differentiated neurons (in the brain and spinal cord). Thus, as understood by previous animal model studies, recovery from viral

infection and the clearance of viral RNA requires the presence of virus-specific antibodies and interferon gamma (IFN- γ) secretion from T cells [24-26]. Along with the B cell, the T cell also play a critical role in immune response against NiV infection. In recent studies a number of B cell and T cell epitopes from the NIPAH proteome have been reported [27-38]. Most of these epitopes show strong interaction tendency with their respective HLA molecule binders. Further different approaches were proposed for the design of multi epitope vaccines [39, 40]. The proposed vaccines utilized a limited number (6 to 8) of T and B cell epitopes. The use of limited number of epitopes could be challenging for the successful presentation of the exogenous vaccine candidates in view of the proteolytic cleavage by Antigen Presenting Cells (APC).

In present study we have screened out the most potential Cytotoxic T lymphocyte (CTL) epitopes, Helper T lymphocyte (HTL) and B cell epitopes from the NiV proteome. We have shortlisted and priotized the most potential and highest scoring 33 CTL, 38 HTL and 16 B cell epitopes. We further studied several critical properties (like IC(50), Immunogenicity, Conservancy, Non-toxic etc) to identify the most potential epitopes against Nipah virus. The shortlisted epitopes were utilized for the design of CTL and HTL multi-epitope vaccines against Nipah virus. The designed vaccines were further studied for their stable interaction with immunological receptor the Toll-Like Receptor 3 (TLR3). The analysis of cDNA of the designed multi-epitope vaccine has predicted to be highly favorable for expression in mammalian cell line. Overall in the present study we have designed and proposed potential multi-epitope vaccines against

Nipah virus infection.

METHODOLOGY

In the present study, we have designed two multi-epitope vaccines (MEVs) composed of thoroughly screened most potential Cytotoxic T lymphocyte (CTL) epitopes and Helper T lymphocyte (HTL) epitopes derived from the nine NiV proteins (glycoprotein (gi-253559848); C protein (gi-1859635642); fusion protein (gi-13559813); matrix protein (gi-13559811); nucleoprotein (gi-1679387250); phosphoprotein (gi-1802790259); V protein (gi-1802790260); RNA polymerase (gi-15487370); W protein (gi-374256971)). CTL and HTL epitopes would be the most potential vaccine candidates since they are responsible for cell-mediated immune response by their presentation on the surface of antigen presenting cells (APCs) by their respective Class I and II human leukocyte antigen (HLA) allele binders. Both the CTL and HTL epitopes chosen for MEV design also carry overlapping regions of linear B cell epitopes. Moreover, both the MEVs also carry potential discontinuous B cell epitopes as well as IFN- γ inducing epitopes in their tertiary structure model. Hence both the designed MEVs carry potential to elicit cell-mediated as well as humoral immune response. Furthermore, both the MEVs were designed with human β Defensin 2 and human β Defensin 3 as adjuvant at their N and C termini to enhance the immunogenic response [41-42]. The β -defensins have considerable immunological adjuvant activity. The β -defensins 2 & 3 have been shown in previous studies to generate potent humoral immune responses when fused with B-cell lymphoma epitopes in

mouse model [43-46]. Since, the pro-inflammatory mediators enhance the expression of β -defensins 2 & 3 in airway epithelial cells we chose β -defensins in our study. The selected CTL and HTL epitopes were validated for their stable molecular interactions with their respective HLA alleles binders; for CTL epitopes, their molecular interaction with human Transporter associated with antigen processing (TAP) was also analyzed [47, 48]. This analysis validated the CTL epitopes that get transported through the TAP cavity for their presentation on cell surface or not. The human TAP selectively pumps cytosolic peptides into the lumen of the endoplasmic reticulum in an ATP-dependent manner [49]. The tertiary structure models of both the MEVs were generated, refined, and further docked with the human Toll-Like Receptor 3 (TLR3), which is an essential immunoreceptor in this pathway [50, 51]. The nuclear localization of Nipah virus W protein inhibits the signaling pathway of TLR3 upon pathogenesis to suppress the TLR3 induced activation of the IFN response to eventually prevent relay of the warning signals to uninfected cells. TLR3 is preferentially expressed by human astrocytes of the central nervous system (CNS) upon infection. The NiV infection involves invasion of the neurons of CNS and hence causes infection in CNS. These studies indicate the importance of the TLR3 responses in immune response and hence TLR3 has been chosen to be studied for its stable binding with the designed multi-epitope vaccines [52-55]. The complexes of CTL and HTL MEVs formed with the human TLR3 were further analysed for their stable molecular interaction by a molecular dynamics simulation study. The cDNA of the designed MEVs were generated and analysed for their high expression tendency

in the mammalian host cell line (Human). Overall, from the present *in-silico* study, we may put forward the design of two MEVs, which qualify all the significant criteria for being a potential vaccine candidate against NiV infection. The corresponding workflow is shown in Supplementary figure S1.

NiV proteins selected for potential epitope screening. In the present study, nine NiV proteins were used for epitope screening. They include C protein, Fusion glycoproteins (F), Glycoproteins (G), Matrix proteins (M), Nucleocapsid protein, Phosphoprotein, Polymerase, V protein and the W protein. The full-length protein sequences of NiV proteins were retrieved from the NCBI database (National Center for Biotechnology Information (<https://www.ncbi.nlm.nih.gov/protein>)). A total of 161 protein sequences available at NCBI, belonging to different strains and origins of NiV, were retrieved. For structural based epitope screenings available tertiary structures of NiV proteins were retrieved from Protein Data Bank (PDB) (<http://www.rcsb.org/pdb/home/home.do>). For the NiV proteins with no structure available, homology models were generated by Swiss-model, (<http://swissmodel.expasy.org/>) [56] (Supplementary table S1).

Screening of Potential Epitopes

T cell Epitope Prediction

Screening of Cytotoxic T lymphocyte (CTL) Epitope. The screening of Cytotoxic T lymphocyte epitopes was performed by the IEDB (Immune Epitope Database) tool “Proteasomal cleavage/TAP transport/MHC class I combined predictor”

(<http://tools.iedb.org/processing/>) [57-59]. Proteasome cleavage score depend on the total amount of cleavage site in the protein. TAP score estimates an effective $\log_{10}(-IC_{50})$ values (half maximal inhibitory concentration (IC_{50})) for binding to TAP of a peptide or its N-terminal prolonged precursors. The MHC binding prediction score is $-\log_{10}(IC_{50})$ values for binding to MHC of a peptide [60]. The tool gives a “Total Score” which is a combined score of the proteasome, MHC, TAP (N-terminal interaction), and processing analysis scores. The total score is generated by using the combination of six different methods viz. Consensus, NN-align, SMM-align, Combinatorial library, Sturniolo and NetMHCIIpan. The IC_{50} (nM) value for each epitope and MHC allele binding pairs were also obtained by this IEDB tool. Epitopes having high, intermediate, and least affinity of binding to their HLA allele binders have IC_{50} values < 50 nM, < 500 nM and < 5000 nM respectively. Immunogenicity of all the screened CTL epitopes was also obtained by using “MHC I Immunogenicity” tool of IEDB (<http://tools.iedb.org/immunogenicity/>) with all the parameters set to default analyzing 1st, 2nd, and C-terminus amino acids of the given screened epitope [60]. The tool predicts the immunogenicity of a given peptide-MHC (pMHC) complex on the basis of the physiochemical properties of constituting amino acid and their position within the peptide sequence.

Screening of Helper T lymphocyte (HTL) Epitopes. To identify the Helper T lymphocyte epitopes from NiV proteins, the IEDB tool “MHC-II Binding Predictions” (<http://tools.iedb.org/mhcii/>) was used. Peptides with IC_{50} values

<50 nM are considered high affinity, <500 nM intermediate affinity and <5000 nM low affinity [61-64]. The tool generates percentile rank for each potential peptide. This percentile rank is generated by the combination of three different methods viz. combinatorial library, SMM_align and Sturniolo and by comparing the score of the peptide against the scores of other random five million 15-mer peptides of SWISSPROT database [61-64]. The rank from the consensus of all three methods was generated by the median percentile rank of the three methods. Lower the value of percentile, higher would be the rank.

Population Coverage by CTL and HTL epitopes. The “Population Coverage” tool of IEDB (<http://tools.iedb.org/population/>) was used to elucidate the world human population coverage by the shortlisted 33 CTL and 38 HTL epitopes derived from nine NiV proteins [65]. The T cells recognize complex between a specific major MHC molecule and a particular pathogen-derived epitope. The given epitope will elicit a response only in an individual that express an MHC molecule, which is capable of binding that particular epitope. This denominated MHC restriction of T cell responses and the MHC polymorphism provide basis for population coverage study. The MHC types are expressed at dramatically different frequencies in different ethnicities. Hence a vaccine with larger population coverage could be of greater importance [65]. Clinical administration of multiple-epitopes involving both the CTL and the HTL epitopes are predicted here to have a greater probability of larger human population coverage worldwide.

B Cell Epitope Prediction

Sequence-based B Cell epitope prediction. Protein sequence-based six different methods were utilized to screen linear B cell epitopes from nine different NiV proteins. These methods are available at “B Cell Epitope Prediction Tools” of IEDB server (<http://tools.iedb.org/bcell/>). In this screening the parameters such as hydrophilicity, flexibility, accessibility, turns, exposed surface, polarity and antigenic propensity of the polypeptides are correlated with their localization in the protein. This allows the search for continuous epitopes prediction from protein sequence. The prediction is based on the propensity scales for each of the 20 amino acids. For a window size n , the $i - (n-1)/2$ neighboring residues on each side of residue i are used to compute the score for the residue i [66-71]. These methods utilize the propensity scale method as well as the physiochemical properties of the given antigenic sequence to screen potential epitopes using “Bepipred Linear Epitope Prediction”, “Chou & Fasman Beta-Turn Prediction”, “Emini Surface Accessibility Prediction”, “Karplus & Schulz Flexibility Prediction”, “Kolaskar & Tongaonkar Antigenicity” and “Parker Hydrophilicity Prediction” tools [66-71].

Structure-based B cell epitope prediction. The ElliPro (ElliPro: Antibody Epitope Prediction tool; <http://tools.iedb.org/ellipro/>) and the DiscoTope2.0 (DiscoTope: Structure-based Antibody Prediction tool; <http://tools.iedb.org/discotope/>) methods available at IEDB, were used to screen the linear and the discontinuous B cell epitopes [72, 73]. The ElliPro method analyses on the basis of the location

of residue in the protein's 3D structure. The residues lying outside of an ellipsoid covering 90% of the inner core protein residues score highest Protrusion Index (PI) of 0.9; and so on. The discontinuous epitopes predicted by the ElliPro tool are clustered on the basis of the distance "R" in Å between two residue's centers of mass lying outside of the largest possible ellipsoid. The larger value of R indicates larger distant residues (residue discontinuity) are screened in the epitopes. The Discotope 2.0 method is based on the "contact number" of the residue's C α carbon atom as well as on the propensity of a given residue to be a part of an epitope [72, 73]. The residue "contact number" is the number of C α atoms in the antigen within a distance of 10 Å of the particular residue's C α atom. A low contact number would indicate the residue being close to the surface or in protruding regions of the antigen's structures.

Characterisation of potential epitopes

Epitope conservation analysis. The shortlisted CTL, HTL and B cell epitopes screened from nine NiV proteins were analysed for the conservancy of their amino acid sequence by "Epitope Conservancy Analysis" tool (<http://tools.iedb.org/conservancy/>) of IEDB. The epitope conservancy is the fraction of protein sequences that contain that particular epitope. The analysis was done against their entire respective source protein sequences of NiV proteins retrieved from the NCBI protein database [74].

Epitope Toxicity prediction. The tool ToxinPred

(http://crdd.osdd.net/raghava/toxinpred/multi_submit.php) was used to analyse the toxicity of shortlisted CTL, HTL and B cell epitopes. The tool allows to identifying highly toxic or non-toxic short peptides. The toxicity check analysis was done by the “SVM (Swiss-Prot) based” (support vector machine) method utilizing dataset of 1805 sequences as positive, 3593 negative sequences from Swissprot as well as an alternative dataset comprises the same 1805 positive sequences and 12541 negative sequences from TrEMBLE [75].

Overlapping residue analysis. The overlapping residue analysis for the shortlisted CTL, HTL and the B cell linear epitopes was performed by the Multiple Sequence Alignment (MSA) analysis by Clustal Omega tool (<https://www.ebi.ac.uk/Tools/msa/clustalo/>) of EBI (European Bioinformatics Institute) [76]. The Clustal Omega multiple sequence alignment tool virtually aligns any number of protein sequences and delivers an accurate alignment.

Epitope selected for molecular interaction study with HLA allele and TAP transporter. On the basis of the overlapping residue analysis of shortlisted CTL, HTL and linear B cell epitopes few numbers of CTL and HTL epitopes were chosen for further analysis involving stable interaction with their respective HLA allele binders and TAP cavity interaction (Supplementary table S3 & S4, Figure 3). These epitopes were chosen on the basis of them having partial or full overlapping sequence region amongst all three types of epitopes (CTL, HTL and B Cell), or having full sequence overlap amongst any of the two types of

epitopes, or having the highest number of the HLA allele binders.

Molecular interaction analysis of selected epitopes with HLA allele and TAP transporter.

Tertiary structure modelling of HLA alleles and selected T cell epitopes. The Swiss-model was used for homology modelling of the HLA class I and II allele binders of shortlisted epitopes [56]. The amino acid sequence of the HLA allele binders were retrieved from Immuno Polymorphism Database (IPD-IMGT/HLA) (<https://www.ebi.ac.uk/ipd/imgt/hla/allele.html>). Templates for homology modelling were chosen on the basis of highest amino acid sequence similarity. All the HLA allele models were further validated by their QMEAN value. The QMEAN value gives a composite quality estimate involving both global as well as local analysis of the model [77]. Generated Model having acceptable QMEAN value (cutoff -4.0) were chosen for further studies (Supplementary table S2).

The “Natural Peptides Module for Beginners” module of PEPstrMOD (http://osddlinux.osdd.net/raghava/pepstrmod/nat_ss.php) was utilized to generate tertiary structures for the selected CTL and HTL epitopes [78]. The time window for simulation was set to 100 picoseconds (ps) in a vacuum environment.

Molecular interaction analysis of selected CTL and HTL epitopes with HLA alleles. The AutoDock 4.2 (ADT) and the AutoDock Vina were used for *in-silico* molecular docking study of the selected CTL and HTL epitopes with their respective HLA class I and II allele binders [79, 80]. The generated docked

complexes were studied for their stable nature by molecular dynamics simulation. MD simulation was performed by the Gromacs 5.1.4 using the Optimized Potential for Liquid Simulations - all-atom force field (OPLS-AA) [81, 82].

Molecular interaction analysis of selected CTL epitopes with TAP transporter.

TAP transporter plays an important role in the presentation of CTL epitope. From the cytosol after proteasome processing, the fragmented peptide of foreign protein gets transported to endoplasmic reticulum (ER) through the TAP transporter, from the ER these short peptides reach to the Golgi bodies and then get presented on the cell surface [83]. Molecular interaction study of the shortlisted CTL epitopes with the TAP transporter cavity was performed by molecular docking using AutoDock Vina [79, 80]. As structural model the cryo-EM structure of TAP transporter (PDB ID: 5u1d) after removing the antigen from TAP cavity of the original structure [48] was used for epitope-TAP interaction study.

Design, characterisation and molecular interaction analysis of Multi-Epitope Vaccines with immunological receptor.

Design of Multi-Epitope Vaccines. All the screened CTL and HTL epitopes were utilized to design CTL and HTL Multi-Epitope vaccines. Short peptides EAAAK and GGGGS were used as rigid and flexible linkers respectively (Figure 1). The GGGGS linker provides proper conformational flexibility to the vaccine tertiary structure and hence facilitates stable conformation to the vaccine. The EAAAK

linker facilitates in domain formation and hence facilitates the vaccine to obtain its final stable structure [84-86]. The human beta-defensin 2 (hBD-2) (PDB ID: 1FD3, Sequence: GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP) and the human beta-defensin 3 (hBD-3) (PDB ID: 1KJ6, Sequence: GIINTLQKYCYCRVRGGRCVLSCLPKEEQIGKCSTRGRKCCRRKK) were used as adjuvants in the design of both the MEVs at N and C terminals respectively [41-46, 87,]. Human Beta-defensins (hBD) have an important role in the chemotactic activity memory T cells, immature dendritic cells and monocytes. Beta-defensins are also involved in degranulation of the mast cells. Due to the important role of hBDs in immune response enhancement, hBDs have been chosen and utilized as adjuvants for the MEV designs.

Figure 1. Design of Multi-Epitope Vaccine (MEVs). (A) CTL and (B) HTL epitopes were linked by the short peptide linker 'GGGGS'. Human β Defensin 2 and β Defensin 3 were used as an adjuvant at the N and C terminals respectively. The short peptide EAAAK was used to link the β Defensin 2 and β Defensin 3. Epitopes from different proteins were coloured in different colours. C terminal 6xHis is designed as His tag. * Epitopes common to Phosphoprotein, V Protein and W protein.

Characterisation of designed Multi-Epitope Vaccines

Interferon gamma inducing epitope prediction. From the designed amino acid sequence of both the MEVs potential interferon gamma (IFN- γ) epitopes were

screened by the “IFNepitope” server
(<http://crdd.osdd.net/raghava/ifnepitope/scan.php>) using “Motif and SVM hybrid”,
(MERCI: Motif-Emerging and with Classes-Identification, and SVM: support
vector machine) method. The tool predicts peptides from protein sequences
having the capacity to induce IFN-gamma release from CD4+T cells. This
module generates overlapping IFN-gamma inducing peptides from query
sequence. . For the screening, IEDB database with 3705 IFN-gamma inducing
and 6728 non-inducing MHC class II binders is utilized [88, 89].

MEVs allergenicity and antigenicity prediction. The designed MEVs were further
analysed for allergenicity and antigenicity prediction by utilizing the AlgPred
(<http://crdd.osdd.net/raghava/algpred/submission.html>) and the Vaxigen
(<http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html>) tools respectively
[90, 91]. The AlgPred prediction is based on the similarity of already known
epitope with any region of the submitted protein. For the screening of
allergenicity, the Swiss-prot dataset consisting of 101725 non-allergens and 323
allergens is utilized [90]. The VaxiJen utilizes an alignment-free approach, solely
based on the physicochemical properties of the query amino acid sequence. For
prediction of antigenicity, the Bacterial, viral and the tumour protein datasets
were used to derive models for the prediction of whole protein antigenicity. Every
set consisted of known 100 antigens and 100 non-antigens [91].

Physicochemical property analysis of designed MEVs. The ProtParam

(<https://web.expasy.org/protparam/>) tool was utilized to analyse the physiochemical properties of the designed CTL and HTL MEVs [92]. The ProtParam analysis performs an empirical investigation for the given query amino acid sequence. ProtParam computes various physicochemical properties derived from a given protein sequence.

Tertiary structure modelling and refinement of MEVs. The tertiary structure of the designed CTL and HTL MEVs were calculated by homology modelling utilizing the RaptorX structure prediction tool (<http://raptorx.uchicago.edu/StructurePrediction/predict/>) [93]. RaptorX predicts template-based secondary and tertiary structures, contacts, solvent accessibility, disordered regions and binding sites for given protein sequence, with or without having close homologs in the Protein Data Bank (PDB). RaptorX also assigns confidence scores to indicate the quality of a predicted 3D model [94-96]. Quality assessment for both the generated homology models of CTL and HTL MEVs was performed by their respective P-values. The P-value for a predicted homology model is a probability score of the generated model being worse than the best. Hence the P-value indicates a relative quality of the generated model in terms of modelling error, combining the global distance test (GDT) and the un-normalized global distance test (uGDT) indicating the error involved at each residue. The smaller the P-value the greater the quality of a predicted model.

The refinement of both the generated MEV models was performed by ModRefiner (<https://zhanglab.ccmb.med.umich.edu/ModRefiner/>) and

GalaxyRefine tool (<http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE>) [97, 98]. Modrefiner improves the physical realism and structural accuracy of the model using a Two-step Atomic-level Energy Minimization. ModRefiner is an algorithm for the atomic-level, high-resolution protein tertiary structure refinement. Both the side-chain and the backbone atoms of protein structure are completely flexible during the structure refinement simulations. The conformational search is guided by a composite of physics and knowledge based force field. The tool generates significant improvement in the physical quality of the local structures [97]. TM-score generated by ModRefiner indicates the structural similarity of the refined model with the original input model. Closer the TM-Score to 1, higher would be the similarity of original and the refined model. The GalaxyRefine tool refines the query tertiary structure by repeated structure perturbation as well as by utilizing the subsequent structural relaxation by the molecular dynamics simulation. The tool GalaxyRefine generates reliable core structures from multiple templates and then re-builds unreliable loops or termini by using an optimization-based refinement method [96, 99]. To avoid any breaks in the 3D model GalaxyRefine uses triaxial loop closure method. The MolProbity score generated for a given refined model indicates the log-weighted combination of the clash score (the number of atomic clashes per 1000 atoms), the Ramachandran favored backbone torsion angles and the percentage of bad side-chain rotamers (the percentages of rotamer outliers). The 'GDT-HA' (Global Distance Test-High Accuracy) generated by the tool indicates the backbone structure accuracy; 'RMSD' (Root mean Square Deviation) indicates the overall

structural deviation in refined model from the initial model and the ‘Rama favored’ indicates percentage of Ramachandran favored residues.

Validation of CTL and HTL MEVs refined models. Both the refined CTL and HTL MEV 3D models were further validated by RAMPAGE analysis tool (<http://mordred.bioc.cam.ac.uk/~rapper/rampage.php>) [100, 101]. The generated Ramachandran plots for the MEV models show the sterically allowed and disallowed residues along with their dihedral psi (ψ) and phi (ϕ) angles.

Discontinuous B-cell epitope prediction from MEVs. Both the generated tertiary models of designed CTL and HTL MEVs were subjected to discontinuous B cell epitopes prediction. The structure-based discontinuous B cell epitopes were screened from both the MEV models by utilizing the ElliPro method as described earlier [72].

Molecular interaction analysis of MEVs with TLR-3

Molecular interaction analysis of both the designed MEVs with Toll-Like receptor-3 (TLR-3), was performed by molecular docking and molecular dynamics simulation. Molecular docking was performed by PatchDock server (<http://bioinfo3d.cs.tau.ac.il/PatchDock/>) [102-104]. PatchDock utilizes algorithm for unbound (real life) docking of molecules for protein-protein. The algorithm carries out the rigid docking, with the surface variability/flexibility implicitly addressed through liberal intermolecular penetration. The algorithm focuses on

the (i) initial molecular surface fitting on localized, curvature based surface patches (ii) use of Geometric Hashing and Pose Clustering for initial transformation detection (iii) computation of shape complementarity utilizing the Distance Transform (iv) efficient steric clash detection and geometric fit scoring based on a multi-resolution shape representation and (v) utilization of biological information by focusing on hot spot rich surface patches [102-104]. For molecular docking, the 3D structure of human TLR-3 ectodomain (ECD) was retrieved from the PDB databank (PDB ID: 2A0Z). Further, the molecular dynamics simulation study of the MEVs-TLR-3 complexes were performed by Gromacs 5.1.4, utilizing the Optimized Potential for Liquid Simulations - all-atom force field (OPLS-AA) [81, 82]. MD simulation was performed to understand the properties of the MEVs-TLR3 complexes in terms of their structure and the microscopic interactions in the complex. The study provides dynamical properties of the designed system with MEVs-TLR3 complexes with a guess at the interactions between the molecules, and also it gives 'exact' predictions of bulk properties. MD Simulations act as a bridge between theory and experiment [81, 82].

***In-silico* analysis of MEVs for cloning and expression**

Analysis of cDNA of the MEVs for cloning and expression in mammalian cell line.

Complementary DNA of both the MEVs, codon optimized for expression in Mammalian cell line (Human) were generated by Java Codon Adaptation Tool (<http://www.jcat.de/>). The generated cDNA were further analysed by GenScript Rare Codon Analysis Tool (<https://www.genscript.com/tools/rare-codon-analysis>).

The tool analyses the GC content, Codon Adaptation Index (CAI) and the Tandem rare codon frequency for a given cDNA [105-107]. The CAI indicates the possibility of cDNA expression in a chosen expression system. The tandem rare codon frequency indicates the presence of low-frequency codons in the given cDNA.

RESULTS & DISCUSSION

Screening of potential epitopes

T cell Epitope Prediction

Screening of Cytotoxic T lymphocyte (CTL) Epitope. Cytotoxic T lymphocyte (CTL) epitopes screened were shortlisted according to the highest “Total Score”, low IC(50) (nM) value for epitope-HLA class I allele complexes, and epitopes with the larger number of the HLA class I allele binders. The immunogenicity of the shortlisted CTL epitopes was also determined; the higher immunogenicity score indicates the greater immunogenic potential of the given epitope (Supplementary table S3, S7). A total of 33 CD8+ T cell epitopes were finally chosen. Out of the 33 CTL epitopes reported here 10 epitopes (Fusion Protein: FALSNGVLF; Glycoprotein: TVYHCSAVY; Nucleocapsid: YPALALNEF; Phosphoprotein: VSDAKMLSY; Polymerase: YPECNNILF, FPVMGNRIY, AEFFSFFRTF, IPFLFLSAY, ETDDYNGIY, SQNLLVTSY) show a match with previous studies [35-38], indicating consensus of epitope screening by different approaches and methods (Supplementary table S3).

Screening of Helper T lymphocyte (HTL) epitopes. The screening of helper T lymphocyte (HTL) epitopes from nine different proteins of NiV was performed on the basis of “Percentile rank”. The smaller the value of percentile rank the higher would be the affinity of the peptide with its respective HLA allele binders. In our initial screening, we got several potential CD4+ T cell epitopes with high scoring. 38 epitopes out of initial screening were shortlisted on the basis that they had highest percentile rank and highest number of HLA class II allele binders (Supplementary table S4, S8).

Population Coverage by CTL and HTL epitopes. The population coverage by the shortlisted epitopes was also studied, in particular involving countries of South Asia, East Asia, Northeast Asia and the Middle East. From this study, we may conclude that the combined use of all the shortlisted CTL and HTL epitopes would have an average worldwide population coverage as high as 97.88%, with a standard deviation of 21.97 (Supplementary table S5).

B Cell epitope prediction

Sequence-based B Cell epitope prediction. In our initial study, we screened a total of 116 B Cell epitope from nine different NiV proteins, with the epitope length of at least four amino acids utilizing the Bepipred Linear Epitope Prediction method. B cell epitopes predicted by another five different methods based on different physiochemical properties were found to have significant consensus with the epitope amino acid sequences predicted by Bepipred Linear Epitope

Prediction. Here, 16 out of the 116 epitopes were shortlisted having a length of 4 to 19 amino acids (Supplementary table S6, Figure 2). One of these 16 B cell epitopes (Matrix Protein: SIPREFMIY) matches with a previous study [39], indicating epitope screening consensus using different approaches and methods (Supplementary table S6).

Figure 2. Overlapping regions amongst the linear B cell epitopes predicted by the BepiPred method and other seven different B cell epitopes prediction methods. B cell epitopes predicted by the BepiPred method and other different protein sequence based (Chou., Emini., Karplus., Kolaskar., and Parker..) and protein structure based (DiscoTope and ElliPro) prediction methods were found to have significant consensus. Consensus overlapping regions of BepiPred epitopes are underlined by the different colour, corresponding to respective prediction method.

Structure-based B cell epitope prediction. Structure-based discontinuous and linear epitopes predicted by the DiscoTope 2.0 and the Ellipro methods have shown a significant consensus of overlapping amino acid sequence with the linear epitopes predicted by BepiPred linear epitopes method (Supplementary table S6, Figure 2). This result further confirms that the shortlisted B Cell BepiPred Linear Epitopes have a high chance of being highly immunogenic epitopes.

Characterisation of potential epitopes

Epitope conservation analysis. Sequence conservation analysis of the shortlisted 33 CTL, 38 HTL and 16 B cell epitopes showed that the '100% amino acid sequence' conservancy of CTL, HTL and B cell epitopes amongst all retrieved NiV protein sequences is mostly 100%, as shown in Supplementary table S3, S4, S6. This result indicates the high conservancy nature of the amino acid sequence of the shortlisted CTL, HTL and B cell epitopes.

Epitope toxicity prediction. Toxicity analysis of all the shortlisted CTL, HTL and B Cell epitopes was also performed. The ToxinPred study indicated the non-toxic nature of all the shortlisted epitopes (Supplementary table S3, S4, S6).

Overlapping residue analysis. Amino acid sequence overlap analysis amongst the shortlisted CTL, HTL and B cell epitopes from nine NiV proteins was performed by using the Multiple Sequence Alignment (MSA) analysis tool Clustal Omega. Our analysis showed that several epitopes of CTL, HTL and B cell have overlapping amino acid sequence. The CTL, HTL and B cell epitopes having two or more amino acids overlap are shown in Figure 3.

Figure 3. Overlapping CTL, HTL and B cell epitopes. Multiple sequence alignment performed by Clustal Omega at EBI to identify the consensus overlapping regions of CTL (red), HTL (blue) and B cell epitopes (green) amongst shortlisted epitopes. Epitopes with overlapping region amongst all the

three types of epitopes (CTL, HTL and B Cell epitopes), epitopes with full sequence overlap and epitopes with the highest number of HLA allele binders were chosen for further studies (encircled).

Epitope selected for molecular interaction study with HLA allele and TAP transporter. Amongst all the shortlisted epitope peptides seven CTL and seventeen HTL epitope peptides have partial or full overlapping sequences or have the highest number of HLA allele binders were shortlisted for further studies (Figure 3, Supplementary table S3 & S4).

Molecular interaction analysis of selected epitopes with HLA allele and TAP transporter.

Molecular interaction analysis of selected CTL and HTL epitopes with HLA alleles. The molecular docking study of the shortlisted CTL and HTL epitopes with their respective HLA class I and II allele binders was performed using AutoDock Vina. Docking studies revealed for all epitopes significant molecular interaction with their HLA allele binders having low binding energies and multiple hydrogen bonds formed (Figure 4A & 4B). The stability of the obtained docking complexes was further tested by molecular dynamics (MD) simulation studies. MD simulations were performed over a time interval of 0.5-1 ns at the invariable temperature of ~ 300 K and at invariable pressure of ~ 1 bar. All the complexes showed reasonably invariant root mean square deviation (RMSD) value (between ~ 0.2 to 0.4 nm) indicating the stable nature of the tested epitope-HLA

allele complexes (Figure 5A & 5B). Moreover, the reasonably invariant Rg (radius of gyration) of the complexes, throughout the MD simulation (Supplementary figure S2), and the root mean square fluctuation (RMSF) for all the atoms of the complexes (Supplementary figure S3) again indicate the stable nature of the epitopes and HLA allele complexes. Furthermore, the B-factor analysis of all the epitope-HLA allele complexes indicated most of the complex regions to be stable (blue) with a very small region being acceptably fluctuating (yellow and orange) (VIBGYOR colour presentation) Supplementary figure S4.

Figure 4. (A) Molecular Docking analysis of CTL epitopes and HLA alleles.

Molecular docking of selected CTL epitopes (cyan sticks) with their respective HLA class I allele binders (gray sticks). The study shows the docked complexes to have significantly negative binding energy along with hydrogen bonds (green dots) formation in the complex interface. **(B) Molecular Docking analysis of HTL epitopes and HLA alleles.** Molecular docking of selected HTL epitopes (cyan sticks) with their respective HLA class II allele binders (gray sticks). The study shows the docked complexes to have significantly negative binding energy along with hydrogen bonds (green dots) formation in the complex interface.

Figure 5. (A) Molecular Dynamics simulation analysis of CTL epitopes and

HLA allele complexes. Molecular Dynamics simulation study reveals a stable nature of the CTL-HLA allele complexes throughout 0.5-1 ns time window with reasonably invariable RMSD. **(B) Molecular Dynamics simulation analysis of**

CTL epitopes and HLA allele complexes. Molecular Dynamics simulation study reveals a stable nature of the HTL-HLA allele complexes throughout 0.5-1 ns time window with reasonably invariable RMSD.

Molecular interaction analysis of selected CTL epitopes with TAP transporter.

The molecular docking interaction analysis of the chosen CTL epitopes with the TAP transporter cavity showed a significantly strong molecular interaction with low binding energy and several hydrogen bonds formed at different sites of the TAP transporter cavity. Two sites of interaction were of particular interest, one located near the cytoplasmic end and the other in the vicinity of the ER lumen (Figure 6). Our study confirms the transportation feasibility of the chosen CTL epitopes from the cytoplasm into the ER lumen which is essential for the representation of peptides by the HLA allele molecules on the surface of antigen presenting cells.

Figure 6. Molecular docking analysis of CTL epitopes within the TAP transporter cavity. Molecular interaction of CTL epitopes (cyan sticks) within the TAP cavity (gray ribbon/sticks) is shown in detail. For every panel of epitope-TAP complex, **(A)** shows the binding of epitope at two different sites within TAP cavity, **(B)** and **(C)** show detailed molecular interaction between epitopes and TAP cavity; (a, b) show chain A and B of TAP transporter. H-bonds are shown in yellow dots. (*) Binding energy, shown in kcal/mol.

Characterisation and molecular interaction analysis of designed Multi-Epitope Vaccines with immunological receptor

Characterisation of designed Multi-Epitope Vaccines

Interferon-gamma inducing epitope prediction. Interferon-gamma (IFN- γ) inducing epitopes are involved in both the adaptive and the innate immune response. The IFN- γ inducing 15-mer peptide epitopes were screened from the CTL and HTL MEVs by utilizing the IFNepitope server. A total of 33 CTL MEV and 43 HTL MEV INF- γ inducing POSITIVE epitopes with a score of 1 or more than 1 were shortlisted (Supplementary table S9, Figure 7D & 7I).

Figure 7. Tertiary structure modelling of CTL and HTL Multi-Epitope Vaccines. (A) & (F): Tertiary structural models of CTL and HTL MEVs showing epitopes in different colours corresponds to as in Figure 1. **(B) & (G):** Show the different domains of CTL and HTL MEVs. **(C) & (H):** The overlapping linear B cell epitope region present in CTL and HTL MEVs, shown by spheres. **(D) & (I):** From the CTL and HTL MEVs, the INF- γ inducing epitopes are shown in cyan, discontinuous B Cell epitopes are shown in magenta and the region common amongst INF- γ and discontinuous B Cell epitopes are shown in wheat colour. **(E) & (J):** RAMPAGE analysis of the refined CTL and HTL MEV models.

MEVs allergenicity and antigenicity prediction. Both the CTL and HTL MEVs were analyzed to be NON-ALLERGEN by the AlgPred analysis scoring - 0.61243421 and -0.93493027 respectively while default threshold value being -

0.4. CTL and HTL MEVs were also analyzed by VaxiJen to be probable ANTIGENS with the prediction score of 0.4447 and 0.4836 respectively, while the default threshold value for viral proteins being 0.4. Hence, with the mentioned analysis tools both the CTL and HTL MEVs are predicted to be non-allergic as well as antigenic in nature.

Physicochemical property analysis of designed MEVs. ProtParam analysis were performed for both the CTL and HTL MEVs to analyse their physiochemical properties. The CTL MEV is composed of 576 amino acids, has a molecular weight of 58.57 kDa and a theoretical pI of 8.19. The expected half-life of the CTL MEV in *E.coli*, yeast and mammalian reticulocytes were predicted with 10 h, 20 min, and 30 h respectively; the aliphatic index of CTL MEV was found to be 58.42, and grand average of hydropathicity (GRAVY) of CTL MEV was found to be -0.010, both indicating globular and hydrophilic nature of the CTL MEV. The instability index score of the CTL MEV was 48.03 indicating its stable folding under native conditions.

Further, the ProtParam analysis of the HTL MEV showed for the 857 amino acids, a molecular weight of 87.62 kDa and a theoretical pI of 5.99. The expected half-life of HTL MEV in *E.coli*, yeast and mammalian reticulocytes was predicted to be 10 h, 20 min and 30 h, respectively. The aliphatic index of HTL MEV was calculated as 82.99, and the grand average of hydropathicity (GRAVY) of the HTL MEV was found to be 0.188, both indicating that HTL MEV has a globular and hydrophilic nature. The instability index of the HTL MEV was 45.66

indicating its stable nature.

Tertiary structure modelling and refinement of MEVs. 3D homology models were generated for both the CTL and HTL MEVs by utilizing the RaptorX modelling tool (Figure 7A, 7F). The model obtained for CTL MEV has 6% helix, 27% β -sheet, 66% coil content and structural elements are 23% exposed, 39% medium and 36% buried. The structural model has three domains ranging from amino acid 1 to 46 (1st domain, template-1fd3:A), 47 to 520 (2nd domain, templates-1yrzA, 1y7bA, 5jozA, 3zxjA, 5z5dA) and 521 to 576 (3rd domain, template-1kj6:A) (Figure 7B). Similarly, the 3D model calculated with RaptorX for the HTL MEV has 21% helix, 22% β -sheet, 56% coil content with 24% of the amino acids exposed, 39% medium and 36% buried. The structural model has three domains ranging from amino acid 1 to 46 (1st domain, template-1fd3:A), 47 to 801 (2nd domain, templates-5m5zA, 3eqnA), 802 to 857 (3rd domain, template-1kj6:A) (Figure 7G). The P-Value for the best template based CTL and HTL MEV homology models were 2.79e-04 and 5.99e-03 respectively. Good quality, mostly alpha proteins have a P-value of less than 10^{-3} and that of mostly beta proteins has a P-value of less than 10^{-4} . Hence both the homology models of CTL and HTL MEVs are predicted to be of good quality. Since for the CTL and HTL MEV design, the CTL and HTL epitopes used also show overlapping common regions with the linear B cell epitopes (Figure 2), both the generated CTL and HTL MEV models also carry the overlapping regions of linear B Cell epitopes (Figure 7C, 7H).

The generated CTL and HTL 3D models were further refined using ModRefiner to fix structural gaps followed by GalaxyRefine refinement. Refinement with ModRefiner showed a TM-score of 0.9703 and 0.8934 for the CTL and HTL models respectively, both being close to 1 indicating the initial and the refined models were structurally similar. For the CTL MEV model refinement, the score of models 1 for different parameters were, Rama favored was 90.8%, GDT-HA was 0.9596, RMSD was 0.385, MolProbity was 2.673, Clash score was 29.9, and Poor rotamers was 1.8. Likewise for HTL MEV model refinement, the score of models 1 for different parameters were, Rama favoured was 88.5%, GDT-HA was 0.9463, RMSD was 0.419, MolProbity was 2.811, Clash score was 38.4, and Poor rotamers was 1.6. Here, MolProbity shows the log-weighted combination of the clash score, percentage Ramachandran not favoured and the percentage bad side-chain rotamers. After refinement, all the mentioned parameters were significantly improved in comparison to the initial CTL and HTL MEV models (Supplementary table S10).

Validation of CTL and HTL MEVs refined models. Both the CTL and HTL model were analysed with the RAMPAGE analysis tool after refinement. The refined CTL MEV model has 91.5% residues in favored regions, 6.8% residues in allowed regions, and only 1.7% residues in the outlier region; while the refined HTL MEV model was found to have 89.5% of residues in favored region, 8.7% residues in allowed region, and 1.9% residues in the outlier region (Figure 7E, 7J).

744

745 *Discontinuous B-cell epitope prediction from MEVs.* Discontinuous B-cell
746 epitopes were further predicted from the final refined 3D models of CTL and HTL
747 MEVs utilizing the ElliPro tool on IEDB server. The screening revealed that the
748 CTL MEV carries 3 and the HTL MEV has 2 potential discontinuous epitopes.
749 The PI (Protrusion Index) score of the CTL MEV discontinuous B cell epitopes
750 ranges from 0.682 to 0.747 and that of HTL MEV it ranges from 0.687 to 0.745
751 (Supplementary table S11, Figure 7D & 7I). The higher PI score indicates a
752 greater potential of the discontinuous B cell epitope.

753

754 ***Molecular interaction analysis of MEVs with TLR-3 .***

755 The refined models of CTL and HTL MEVs were further studied for their
756 molecular interaction with the ectodomain (ECD) of human TLR-3. Therefore,
757 molecular docking of CTL and HTL MEVs model with the TLR-3 crystal structure
758 model (PDB ID: 2A0Z) was performed utilizing the PatchDock tool. Generated
759 docking conformation with highest scores of 22382 and 18264 for CTL and HTL
760 MEVs, respectively were selected for further studies. The highest docking score
761 predicted with the PatchDock tool indicates the best geometric shape
762 complementarity fitting conformation of MEVs and the TLR-3 receptor. Both, the
763 CTL and HTL MEVs were fitting into the ectodomain region of TLR-3 after
764 docking (Figure 8A & 8E). The CTL and HTL MEVs have shown to form multiple
765 hydrogen bonds within the ectodomain cavity region of TLR-3. Further, the
766 molecular dynamics simulation study was also performed for the docked

complexes of both the MEVs and TLR-3. In MD simulations both the complexes have shown reasonably stable RMSD value between ~ 0.2 to 0.5 nm for a given time window of 10 ns at invariable pressure (~ 1 bar) and temperature (~ 300 K) (Figure 8B & 8F). The reasonably invariant radius of gyration (Rg) of both MEVs-TLR-3 complexes (Figure 8C & 8G), and RMS fluctuation (RMSF) for all the atoms in both the complexes (Figure 8D & 8H) indicate that the MEVs-TLR3 complexes are stable. The B-factor analysis of MEVs-TLR3 complexes was also performed. The B-factor indicates the displacement of the atomic positions from an average (mean) value i.e. the more flexible an atom is the larger the displacement from the mean position will be (mean-squares displacement) (Figure 8A and 8E). The areas with high B-factors are colored red (hot), while low B-factors are colored blue (cold) (VIBGYOR presentation). The B-factor of most of the regions of MEVs-TLR3 complexes indicates the stable nature of the complexes while a very small region is found to be fluctuating. The results suggest a stable complex formation tendency for both the CTL and HTL MEVs with the ectodomain of the human TLR-3 receptor.

Figure 8. Molecular Docking and dynamics simulation study of CTL and HTL MEVs with TLR-3. (A) CTL and (E) HTL MEVs (VIBGYOR) docked complex with TLR-3 (gray). Both the complexes are forming several hydrogen bonds in the MEV and TLR-3 interface, as shown by green dots. B-Factor of the docked MEVs is shown by a rainbow (VIBGYOR) presentation. The regions in blue being indicated stable and the region in red indicate unstable. In the above

complexes, most of the region of docked MEVs is in blue and with the very small region is green, yellow or orange, hence the complexes are predicted to be very stable. **(B)** and **(F)**, RMSD as generated by the molecular Dynamics simulation study of CTL, HTL MEVs and TLR-3 complexes. **(C)** & **(G)** Rg (radius of gyration) across the time window of 10 nanosecond. **(D)** & **(H)**, RMS fluctuation for all the atoms of the CTL, HTL MEVs and TLR-3 complexes.

***In-silico* analysis of MEVs for cloning and expression**

Analysis of cDNA of both the MEVs for cloning and expression in mammalian cell line. Complementary DNA codon optimized for CTL and HTL expression in mammalian host cell lines (Human) was generated with the Java Codon Adaptation Tool. The generated optimized cDNA's for both the MEVs were also analysed by utilizing the GenScript Rare Codon Analysis Tool revealing aGC content of optimized CTL-MEV cDNA of 69.79% and a CAI (Codon Adaptation Index) score of 1.00 with 0% tandem rare codons. Likewise, the GC content of the optimized HTL-MEV cDNA was 70.69%, CAI score was 1.00 with 0% tandem rare codons. Since for higher possibility for cDNA expression in human expression system, the GC content of a cDNA should be within the range of 30% to 70%, the CAI score should be between 0.8-1.0, and the tandem rare codon frequency that indicates the presence of low-frequency codons, should be <30%, the cDNA constructs of CTL and HTL MPVs are expected to have high potential for expression in human expression system. The tandem rare codons may hinder the proper expression of the cDNA or even interrupt the translational machinery

of the chosen expression system. According to the GenScript Rare Codon Analysis the cDNA of both the MEVs satisfy all the mentioned parameters and are predicted to have high expression in the mammalian host cell line (Human).

CONCLUSION

In the present study, we have designed and validated two multi-epitope vaccines derived from CTL and HTL epitopes. The selected peptides show significant sequence overlap with screened linear B cell epitopes. Both the CTL and HTL MEVs tertiary models carry potential discontinuous B cell epitopes and INF- γ epitopes. Consequently, the designed MEVs might have the potential to elicit profound humoral and cellular immune responses. Human β -Defensin 2 and 3 fused to the N and C terminal ends of both the MEVs serving as adjuvants to enhance the immune response. The identified epitopes for the CTL and HTL MEVs were also validated by molecular docking and MD simulation studies to test the interaction with their respective HLA allele binders. Molecular interaction of the selected CTL epitopes within the TAP transporter cavity was also evaluated indicating a favorable transport of epitopes from cytoplasm to lumen of Endoplasmic Reticulum for further presentation on cell surface by Golgi bodies. Our analysis of the shortlisted CTL and HTL epitopes combined revealed coverage of 97.88% world human population. The molecular interaction analysis of both the CTL and HTL MEVs with the immunoreceptor TLR3 showed structural fit of the MEVs into the ectodomain of TLR3 receptor cavity and the MD simulations indicate a very stable complex formation. Since both the CTL and

HTL MEVs carry CTL, HTL as well as discontinuous B cell epitopes, the combined administration of both the MEVs, is predicted to elicit both the humoral as well as cell-mediated immune response. The cDNA for both the MEVs were designed considering codon-bias for the expression in mammalian host cell lines (Human). The cDNAs were optimized with respect to their GC content and zero tandem rare codons to gain high expression in mammalian host cell lines (Human). In future experimental studies the designed CTL and HTL MEVs should be cloned, expressed and validated *in-vivo* and in animal trails as potential vaccine candidates against NiV infection.

Supplementary figure S1. Workflow chart.

Supplementary figure S2. (A) Rg (radius of gyration) for the CTL epitope – HLA class I allele complexes, across the time window of 1 nano second. **(B)** Rg for the HTL epitope – HLA class II allele complexes, across the time window of 1 nano second.

Supplementary figure S3. (A) RMS fluctuation in nanometers for all the atoms of the CTL epitope – HLA class I allele complexes. **(B)** RMS fluctuation in nanometers for all the atoms of the HTL epitope – HLA class II allele complexes.

Supplementary figure S4. (A) B-Factor of CTL epitope – HLA class I allele complexes **(B)** B-Factor of HTL epitope – HLA class II allele complexes. Epitopes are shown in sticks and HLA alleles are shown in gray cartoons. B-factor is indicated by rainbow (VIBGYOR) colour, blue for stable region and red for most unstable region.

Supplementary table S1. Protein sequence retrieval, tertiary structures retrieval and homology modeling of nine Nipah proteins. Nipah protein sequences were retrieved from NCBI. Available structure files (pdb) for Nipah proteins were retrieved from RCSB PDB. Nipah proteins with no tertiary structure available were subjected to homology modeling by Swissmodel.

Supplementary table S2. Homology modeling for HLA alleles. Tertiary structure of HLA alleles were modeled by homology modeling using SwissModel

server. Templates were chosen with highest sequence identity. Generated models with acceptable QMEAN value were chosen for further studies.

Supplementary table S3. Shortlisted high scoring CTL epitopes. Selected high scoring CTL epitopes and their respective HLA alleles binders are listed. *In-silico* analysis have shown all the selected epitopes to be non-toxic (Non-Toxin) as well as they show significant conservancy. ToxinPred analysis is based on the ToxinPred main dataset used by “ToxinPred” algorithm to predict toxicity of any unknown peptide. # Epitope match with previous studies indicating consensus in epitope screening by different approaches and methods.

Supplementary table S4. Shortlisted high scoring HTL epitopes. Selected high scoring HTL epitopes and their respective HLA alleles binders are listed above. *In-silico* analysis have shown all the selected epitopes to be non-toxic (Non-Toxin) as well as they show significant conservancy.

Supplementary table S5. World population coverage by the shortlisted CTL and HTL epitopes combined. With a standard deviation of 21.97 on an average 97.88% of world population could be covered by the joint administration of selected CTL and HTL epitopes as vaccine candidate.

Supplementary table S6. Shortlisted B Cell epitopes. BepiPred Linear B Cell epitopes showing sequence overlap with CTL and HTL epitopes are shortlisted above. *In-silico* analysis have shown all the selected epitopes to be non-toxic (Non-Toxin) as well as they show significant amino acid sequence conservancy. # Epitope match with previous studies indicating consensus in epitope screening by different approaches and methods.

Supplementary table S7. CTL epitope prediction. Detailed scoring of all screened CTL epitopes and their respective HLA class I allele binders. CTL epitopes were chosen on the basis of high “Total score” and higher number of HLA allele binders. Total score is a combined score of TAP score, MHC score, Proteasome score and Processing score.

Supplementary table S8. HTL epitope prediction. Percentile rank of HTL epitopes and their respective HLA class II allele binders. HTL epitopes were screened on the basis of percentile rank (lower the percentile number, higher the rank) and larger number of HLA allele binders. Last column show the method used for epitope screening.

Supplementary table S9. INF- γ epitopes from CTL and HTL MEVs. INF- γ inducing (POSITIVE) epitopes from CTL and HTL MEVs were screened by using “Motif and SVM hybrid” (MERC1 & SVM) approaches.

Supplementary table S10. Refinement models of CTL and HTL MEVs. CTL and HTL MEVs models were refined by GalaxyWEB server and used for further studies. After refinement in particular Rama favored residues increased significantly.

Supplementary table S11. B Cell discontinuous epitopes of CTL & HTL MEVs. Discontinuous B Cell epitopes predicted by ElliPro (IEDB) from CTL & HTL MEVs.

ACKNOWLEDGEMENTS:

We acknowledge the Advance Instrumentation Research Facility (AIRF) at Jawaharlal Nehru University, New Delhi for providing the advance computational facility to conduct experiments. We also acknowledge Indian Foundation for Fundamental Research (IFFR) for providing resources and funding

FUNDING:

Indian Foundation for Fundamental Research (IFFR)

AUTHOR CONTRIBUTION:

Idea conceived, methodology designed and performed by S.S., critical data analysis and scientific writing was done by S.S. and M.K., facility of MD simulation was provided by A.K.S, draft was finalized by S.S., M.K., A.K.S.

ADDITIONAL INFORMATION:

Authors declare to have no competing interests.

FIGURES:

		A. CTL epitopes	B. HTL epitopes
	<i>β</i> Defensin 2	GIGDPVTCLKSGAICHVPFCPRRYKQIGTCGLPGTKCKKPP	
	C Protein	EAAAK VQMTYNWTQWLQTLTLY GGGS	EAAAK MMASILLTLF GGGS
		DLALSKYLSDLLFVF GGGS	AQITAGVALY GGGS
		LALSKYLSDLLFVFG GGGS	FALSNGVLF GGGS
		ALSKYLSDLLFVFGP GGGS	KYLSDLLFVF GGGS
	Fusion Protein	LSKYLSDLLFVFGPN GGGS	MTIQAISQAF GGGS
		SKYLSDLLFVFGPNL GGGS	AENPVFTVF GGGS
		KYLSDLLFVFGPNLQ GGGS	AVYNNEFY GGGS
		YLSDLLFVFGPNLQD GGGS	LAMDEGYFAY GGGS
		ASFSDWTMIKFGDVL GGGS	TVYHCSAVY GGGS
		FSWDTMIKFGDVLTV GGGS	NYMYLCYGF GGGS
	Glycoprotein	GVYNDAFLIDRINWI GGGS	YMIPTMLEF GGGS
		NDAFLIDRINWISAG GGGS	EIISDIGNY GGGS
		DAFLIDRINWISAGV GGGS	TPFVDSRAY GGGS
		AFLIDRINWISAGVF GGGS	YPALALNEF GGGS
		FLIDRINWISAGVFL GGGS	LDPVVTDDVY*
	Matrix Protein	IPREFMIYDDVFIDN GGGS	LVSDAKMLSY*
		FMIYDDVFIDNTGRI GGGS	MPSDDFSNTF GGGS
		LSSDQVAELAAAVQE GGGS	VSDAKMLSY*
		SSDQVAELAAAVQET GGGS	AEFFSFFRTF GGGS
	Nucleocapsid	SDQVAELAAAVQETS GGGS	ETDDYNGIY GGGS
		DQVAELAAAVQETSA GGGS	FPISRLFNMY GGGS
		QVAELAAAVQETSAG GGGS	FPVMGNRIY GGGS
		*NNGNVCLVSDAKMLS GGGS	IATVYTWAY GGGS
	Phosphoprotein	*NGNVCLVSDAKMLSY GGGS	IMKKSFKAY GGGS
		*GNVCLVSDAKMLS GGGS	IPFLFLSAY GGGS
		*NVCLVSDAKMLS GGGS	KWYECFLFWF GGGS
		*VCLVSDAKMLS GGGS	KYYQIDQPF GGGS
		NIDNIHLAEFFSFF GGGS	LETDDYNGIY GGGS
		IDNIHLAEFFSFFR GGGS	RLFNMYRSY GGGS
		DNIHLAEFFSFFRT GGGS	SQNLVTSY GGGS
		NIHLAEFFSFFRTF GGGS	SYFGLVLVCF GGGS
		IHLAEFFSFFRTFG GGGS	TSDLDFVIFY GGGS
	Polymerase	LELASFLMDRRVILP GGGS	YPECNNILF GGGS
		ELASFLMDRRVILPR GGGS	
		LASFLMDRRVILPRA GGGS	
		ASFLMDRRVILPRAA GGGS	
		LDFVIFYASLTYLRR GGGS	
		FVIFYASLTYLRRGI GGGS	
	<i>β</i> Defensin 3	EAAAK GIINTLQKYYCRVRGGRCVLSCLPREEDIGKCTRGRKCCRRKK	EAAAK HHHHHHH

Figure 1. Design of Multi-Epitope Vaccine (MEVs). (A) CTL and (B) HTL

epitopes were linked by the short peptide linker 'GGGGS'. Human β Defensin 2 and β Defensin 3 were used as an adjuvant at the N and C terminals respectively. The short peptide EAAAK was used to link the β Defensin 2 and β Defensin 3. Epitopes from different proteins were coloured in different colours. C terminal 6xHis is designed as His tag. * Epitopes common to Phosphoprotein, V Protein and W protein.

Overlapping regions of predicted B cell BepiPred linear Epitope and epitopes predicted by other protein sequence and structure based methods		Overlapping regions of sequence based B cell linear epitope prediction						Overlapping regions of structure based B cell epitope prediction		
		Chou & Fasman Beta-Turn	Emmi Surface Accessibility	Karplus & Schulz Flexibility	Kolaskar & Tongaonkar Antigenicity	Parker Hydrophobicity	DiscoTope: discontinuous epitopes	Linear	EmPro Discontinuous	
Fusion Protein	215 GPNLQDPVNSM 226	215-226		215-226	215-216	217-226				
Glycoprotein	271 WTPNPNT 278	271-278	271-278	272-278		272-278			271-278	
Glycoprotein	459 SWDTMI 464	459-460							463-464	
Glycoprotein	529 NOTAE 533	529-532	529-533	529-533		529-533				
Matrix Protein	184 SGIVM 188	184-188		184-188		184-188				
Matrix Protein	330 SIPREFMIY 338	330-335		330-336		331-334	332-333	332-333	333-338	
Matrix Protein	340 DYFIDNTGRI 349	341-349		340-349		340-344			340-349	
Phosphoprotein	125 GYGFTSPERGWSDYSGA 143	125-143	130-136	128-143		127-143				
Phosphoprotein	163 IAVSKEDR 170	166-170	166-170	163-170	163-166	165-170				
Polymerase	346 NIDN 349	348-349								
Polymerase	364 GHPILE 369	364-367			365-369				366-369	
Polymerase	1095 DKSFDELEL 1104	1096-1103	1096-1101	1095-1104		1096-1103			1095-1104	
Polymerase	1108 LMDR 1111								1108-1111	
Polymerase	1409 LRLETDDYNG 1418	1412-1418	1410-1416	1412-1418		1411-1418	1409-1417	1409-1417		
Polymerase	1982 GFPIIS 1986	1982-1986		1982-1986	1982-1986				1182-1986	
Polymerase	2004 PVYSNPD 2010	2004-2010	2006-2010	2007-2010	2004-2008	2007-2010			2004-2010	

Figure 2. Overlapping regions amongst the linear B cell epitopes predicted by the BepiPred method and other seven different B cell epitopes prediction methods. B cell epitopes predicted by the BepiPred method and other different protein sequence based (Chou., Emini., Karplus., Kolaskar., and Parker..) and protein structure based (DiscoTope and ElliPro) prediction methods were found to have significant consensus. Consensus overlapping regions of BepiPred epitopes are underlined by the different colour, corresponding to respective prediction method.

Fusion Protein	<p>199-236 LDDLA SKYLSDLLEFVFGPNLQDPVNSMTTQAISQAFG</p> <p> -----KYLSDLLEFV----- -----MTQAISQAF----- </p> <p> -----YLSDLLEFV----- -----GPNLOD----- </p> <p> -----KYLSDLLEFV----- -----GPNLO----- </p> <p> -----SKYLSDLLEFV----- -----GPN----- </p> <p> -----LSKYLSDLLEFV----- -----GP----- </p> <p> -----ALSKYLSDLLEFV----- -----FG----- </p> <p> -----DLASKYLSDLLEFV----- -----FG----- </p> <p> -----GPNLODPVNSMT----- -----TTQAISQAF----- </p>
Glycoprotein	<p>270-293 WITPPNPNTVYHCSAVYNNEFFYV 454-474 YQASFSDWTMIKFGDYLTVP 505-541 EGVYNDAFILDRINWISAGVFLDSNQIAENPVFTYFK</p> <p> -----TVYHCSAVY----- -----AVYNNEFFY----- </p> <p> -----WITPPNPNT----- -----YQASFSDWTMIKFGDYLTVP----- </p> <p> -----ESDWTMIKFGDYLT----- -----VQASFSDWTMIKFGDYLT----- </p> <p> -----ASFSWDITMIKFGDYLT----- -----VQASFSDWTMIKFGDYLT----- </p> <p> -----SWDTMIKFGDYLT----- -----VQASFSDWTMIKFGDYLT----- </p> <p> -----GVYNDAFILDRINWISAGV----- -----FLDSNQIAENPVFTYFK----- </p> <p> -----FLDRINWISAGVFL----- -----AENPVFTYFK----- </p> <p> -----AFILDRINWISAGV----- -----FLDSNQIAENPVFTYFK----- </p> <p> -----DAFLDRINWISAGV----- -----FLDSNQIAENPVFTYFK----- </p> <p> -----NDAFILDRINWISAGV----- -----FLDSNQIAENPVFTYFK----- </p> <p> -----GVYNDAFILDRINWISAGV----- -----FLDSNQIAENPVFTYFK----- </p> <p> -----NOTAE----- </p>
Matrix Protein	<p>183-197 DSGYIMPRTMLEFR 330-350 SIPREFMIYDDVFIDNTGRIL</p> <p> -----SYIMPRTMLEF----- -----SIPREFMIYDDVFIDNTGRIL----- </p> <p> -----DSGYIMPRTMLEFR----- -----330-350 SIPREFMIYDDVFIDNTGRIL----- </p> <p> -----FMIVDDVFIDNTGRIL----- -----SIPREFMIYDDVFIDNTGRIL----- </p> <p> -----IPREFMIYDDVFIDNTGRIL----- -----SIPREFMIYDDVFIDNTGRIL----- </p> <p> -----DVFIIDNTGRIL----- -----SIPREFMIYDDVFIDNTGRIL----- </p> <p> -----SIPREFMIYDDVFIDNTGRIL----- -----SIPREFMIYDDVFIDNTGRIL----- </p>
Nucleocapsid	<p>382-404 LGLSSDQVAELAAVQETSAGRQ</p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE----- -----VSDAKMLSYAPE----- </p> <p> -----NVCLVSDAKMLSYAP----- -----VSDAKMLSYAP----- </p> <p> -----GNVCLVSDAKMLSYA----- -----VSDAKMLSYA----- </p> <p> -----NNGVCLVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----LVSDAKMLSY----- -----VSDAKMLSY----- </p> <p> -----VCLVSDAKMLSYAPE-----</p>

Figure 3. Overlapping CTL, HTL and B cell epitopes. Multiple sequence alignment performed by Clustal Omega at EBI to identify the consensus overlapping regions of CTL (red), HTL (blue) and B cell epitopes (green) amongst shortlisted epitopes. Epitopes with overlapping region amongst all the three types of epitopes (CTL, HTL and B Cell epitopes), epitopes with full sequence overlap and epitopes with the highest number of HLA allele binders were chosen for further studies (encircled).

A. CTL epitopes - HLA Class I allele complexes

B. HTL epitopes - HLA Class II allele complexes

Figure 4 (A). Molecular Docking analysis of CTL epitopes and HLA alleles.

Molecular docking of selected CTL epitopes (cyan sticks) with their respective HLA class I allele binders (gray sticks). The study shows the docked complexes to have significantly negative binding energy along with hydrogen bonds (green dots) formation in the complex interface. **(B) Molecular Docking analysis of**

HTL epitopes and HLA alleles. Molecular docking of selected HTL epitopes (cyan sticks) with their respective HLA class II allele binders (gray sticks). The study shows the docked complexes to have significantly negative binding energy along with hydrogen bonds (green dots) formation in the complex interface.

Figure 5 (A). Molecular Dynamics simulation analysis of CTL epitopes and HLA allele complexes. Molecular Dynamics simulation study reveals a stable nature of the CTL-HLA allele complexes throughout 0.5-1 ns time window with reasonably invariable RMSD. **(B) Molecular Dynamics simulation analysis of CTL epitopes and HLA allele complexes.** Molecular Dynamics simulation study reveals a stable nature of the HTL-HLA allele complexes throughout 0.5-1 ns time window with reasonably invariable RMSD.

Figure 6. Molecular docking analysis of CTL epitopes within the TAP transporter cavity. Molecular interaction of CTL epitopes (cyan sticks) within the TAP cavity (gray ribbon/sticks) is shown in detail. For every panel of epitope-TAP complex, (A) shows the binding of epitope at two different sites within TAP cavity, (B) and (C) show detailed molecular interaction between epitopes and TAP cavity; (a, b) show chain A and B of TAP transporter. H-bonds are shown in yellow dots. (*) Binding energy, shown in kcal/mol.

CTL multi-epitope vaccine:

HTL multi-epitope vaccine:

Figure 7. Tertiary structure modelling of CTL and HTL Multi-Epitope

Vaccines. (A) & (F): Tertiary structural models of CTL and HTL MEVs showing epitopes in different colours corresponds to as in Fig. 1. **(B) & (G):** Show the different domains of CTL and HTL MEVs. **(C) & (H):** The overlapping linear B cell epitope region present in CTL and HTL MEVs, shown by spheres. **(D) & (I):** From the CTL and HTL MEVs, the INF- γ inducing epitopes are shown in cyan, discontinuous B Cell epitopes are shown in magenta and the region common amongst INF- γ and discontinuous B Cell epitopes are shown in wheat colour. **(E) & (J):** RAMPAGE analysis of the refined CTL and HTL MEV models.

Figure 8. Molecular Docking and dynamics simulation study of CTL and HTL MEVs with TLR-3. (A) CTL and (E) HTL MEVs (VIBGYOR) docked complex with TLR-3 (gray). Both the complexes are forming several hydrogen bonds in the MEV and TLR-3 interface, as shown by green dots. B-Factor of the docked MEVs is shown by a rainbow (VIBGYOR) presentation. The regions in blue being indicated stable and the region in red indicate unstable. In the above complexes, most of the region of docked MEVs is in blue and with the very small region is green, yellow or orange, hence the complexes are predicted to be very stable. (B) and (F), RMSD as generated by the molecular Dynamics simulation study of CTL, HTL MEVs and TLR-3 complexes. (C) & (G) Rg (radius of gyration) across the time window of 10 nanosecond. (D) & (H), RMS fluctuation for all the atoms of the CTL, HTL MEVs and TLR-3 complexes.

REFERENCES:

1. Angeletti, S., Presti, A.L., Cella, E. and Ciccozzi, M., 2016. Molecular epidemiology and phylogeny of nipah virus infection: a mini review. *Asian Pacific journal of tropical medicine*, 9(7), pp.630-634.
2. Aguilar, H.C., Henderson, B.A., Zamora, J.L. and Johnston, G.P., 2016. Paramyxovirus glycoproteins and the membrane fusion process. *Current clinical microbiology reports*, 3(3), pp.142-154.
3. Ang, B.S., Lim, T.C. and Wang, L., 2018. Nipah Virus Infection. *Journal of clinical microbiology*, pp.JCM-01875.
4. WHO Report, Surveillance and outbreak alert, Nipah virus; https://www.who.int/health-topics/nipah-virus-infection#tab=tab_1
5. Plowright RK, Becker DJ, Crowley DE, Washburne AD, Huang T, Nameer PO, Gurley ES, Han BA. Prioritizing surveillance of Nipah virus in India. *PLoS Negl Trop Dis*. 2019 Jun 27;13(6):e0007393. doi: 10.1371/journal.pntd.0007393. PMID: 31246966; PMCID: PMC6597033.
6. Thomas, B., Chandran, P., Lilabi, M. P., George, B., Sivakumar, C. P., Jayadev, V. K., Bindu, V., Rajasi, R. S., Vijayan, B., Mohandas, A., & Hafeez, N. (2019). Nipah Virus Infection in Kozhikode, Kerala, South India, in 2018: Epidemiology of an Outbreak of an Emerging Disease. *Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine*, 44(4), 383–387. https://doi.org/10.4103/ijcm.IJCM_198_19
7. Mathieu, C., Guillaume, V., Volchkova, V.A., Pohl, C., Jacquot, F., Looi, R.Y., Wong, K.T., Legras-Lachuer, C., Volchkov, V.E., Lachuer, J. and Horvat, B., 2012. Nonstructural Nipah virus C protein regulates both the early host proinflammatory response and viral virulence. *Journal of virology*, pp.JVI-01203.
8. Liu, Q., Chen, L., Aguilar, H.C. and Chou, K.C., 2018. A stochastic assembly model for Nipah virus revealed by super-resolution microscopy. *Nature communications*, 9(1), p.3050.
9. Johnston, G.P., Contreras, E.M., Dabundo, J., Henderson, B.A., Matz, K.M., Ortega, V., Ramirez, A., Park, A. and Aguilar, H.C., 2017. Cytoplasmic motifs in the nipah virus fusion protein modulate virus particle assembly and egress. *Journal of virology*, pp.JVI-02150.
10. Satterfield, B.A., Cross, R.W., Fenton, K.A., Borisevich, V., Agans, K.N., Deer, D.J., Graber, J., Basler, C.F., Geisbert, T.W. and Mire, C.E., 2016. The Nipah virus C and W proteins contribute to respiratory disease in ferrets. *Journal of virology*, pp.JVI-00215.
11. Lamp, B., Dietzel, E., Kolesnikova, L., Sauerhering, L., Erbar, S., Weingartl, H. and Maisner, A., 2013. Nipah virus entry and egress from polarized epithelial cells. *Journal of virology*, pp.JVI-02696.
12. Weise, C., Erbar, S., Lamp, B., Vogt, C., Diederich, S. and Maisner, A., 2010. Tyrosine residues in the cytoplasmic domains affect sorting and fusion activity of the Nipah virus glycoproteins in polarized epithelial cells. *Journal of virology*, 84(15), pp.7634-7641.
13. Ciancanelli, M.J. and Basler, C.F., 2006. Mutation of YMYL in the Nipah virus

- matrix protein abrogates budding and alters subcellular localization. *Journal of virology*, 80(24), pp.12070-12078.
14. Patch, J.R., Crameri, G., Wang, L.F., Eaton, B.T. and Broder, C.C., 2007. Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. *Virology journal*, 4(1), p.1.
15. Patch, J.R., Han, Z., McCarthy, S.E., Yan, L., Wang, L.F., Harty, R.N. and Broder, C.C., 2008. The YPLGVG sequence of the Nipah virus matrix protein is required for budding. *Virology journal*, 5(1), p.137.
16. Jordan, P.C., Liu, C., Raynaud, P., Lo, M.K., Spiropoulou, C.F., Symons, J.A., Beigelman, L. and Deval, J., 2018. Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. *PLoS pathogens*, 14(2), p.e1006889.
17. Ranadheera, C., Proulx, R., Chaiyakul, M., Jones, S., Grolla, A., Leung, A., Rutherford, J., Kobasa, D., Carpenter, M. and Czub, M., 2018. The interaction between the Nipah virus nucleocapsid protein and phosphoprotein regulates virus replication. *Scientific reports*, 8(1), p.15994.
18. Baronti, L., Eralles, J., Habchi, J., Felli, I.C., Pierattelli, R. and Longhi, S., 2015. Dynamics of the intrinsically disordered C-terminal domain of the Nipah virus nucleoprotein and interaction with the X domain of the phosphoprotein as unveiled by NMR spectroscopy. *ChemBioChem*, 16(2), pp.268-276.
19. Uchida, S., Horie, R., Sato, H., Kai, C. and Yoneda, M., 2018. Possible role of the Nipah virus V protein in the regulation of the interferon beta induction by interacting with UBX domain-containing protein1. *Scientific reports*, 8(1), p.7682.
20. Ludlow, L.E., Lo, M.K., Rodriguez, J.J., Rota, P.A. and Horvath, C.M., 2008. Henipavirus V protein association with Polo-like kinase reveals functional overlap with STAT1 binding and interferon evasion. *Journal of virology*, 82(13), pp.6259-6271.
21. Park, M.S., Shaw, M.L., Munoz-Jordan, J., Cros, J.F., Nakaya, T., Bouvier, N., Palese, P., García-Sastre, A. and Basler, C.F., 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. *Journal of virology*, 77(2), pp.1501-1511.
22. Sakib, M.S., Islam, M., Hasan, A.K.M. and Nabi, A.H.M., 2014. Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach. *Advances in bioinformatics*, 2014.
23. Guillaume, V., Contamin, H., Loth, P., Georges-Courbot, M.C., Lefevre, A., Marianneau, P., Chua, K.B., Lam, S.K., Buckland, R., Deubel, V. and Wild, T.F., 2004. Nipah virus: vaccination and passive protection studies in a hamster model. *Journal of virology*, 78(2), pp.834-840.
24. Koyuncu, O.O., Hogue, I.B. and Enquist, L.W., 2013. Virus infections in the nervous system. *Cell host & microbe*, 13(4), pp.379-393.

- 1640 25. Griffin, D.E. and Metcalf, T., 2011. Clearance of virus infection from the CNS.
1641 Current opinion in virology, 1(3), pp.216-221.
- 1642 26. Kong, D., Wen, Z., Su, H., Ge, J., Chen, W., Wang, X., Wu, C., Yang, C.,
1643 Chen, H. and Bu, Z., 2012. Newcastle disease virus-vectored Nipah
1644 encephalitis vaccines induce B and T cell responses in mice and long-
1645 lasting neutralizing antibodies in pigs. *Virology*, 432(2), pp.327-335.
- 1646 27. Kamthania, M. and Sharma, D.K., 2015. Screening and structure-based
1647 modeling of T-cell epitopes of Nipah virus proteome: an immunoinformatic
1648 approach for designing peptide-based vaccine. *3 Biotech*, 5(6), pp.877-
1649 882.
- 1650 28. Kamthania, M. and Sharma, D.K., 2016. Epitope-based peptides prediction
1651 from proteome of nipah virus. *International Journal of Peptide Research*
1652 *and Therapeutics*, 22(4), pp.465-470.
- 1653 29. Ali, M.T., Morshed, M.M. and Hassan, F., 2015. A computational approach
1654 for designing a universal epitope-based peptide vaccine against Nipah
1655 virus. *Interdisciplinary Sciences: Computational Life Sciences*, 7(2),
1656 pp.177-185.
- 1657 30. kumar Sharma, S., Srivastava, S., Kumar, A. and Srivastava, V., 2021.
1658 Anticipation of Antigenic Sites for the Goal of Vaccine Designing Against
1659 Nipah Virus: An Immunoinformatics Inquisitive Quest. *International Journal*
1660 *of Peptide Research and Therapeutics*, pp.1-13.
- 1661 31. Dey, S., Roy, P., Dutta, T., Nandy, A. and Basak, S.C., 2018. Rational
1662 Design of Peptide Vaccines for the Highly Lethal Nipah and Hendra
1663 Viruses. *bioRxiv*, p.425819.
- 1664 32. Krishnamoorthy, P.K., Subasree, S., Arthi, U., Mobashir, M., Gowda, C. and
1665 Revanasiddappa, P.D., 2020. T-cell Epitope-based Vaccine Design for
1666 Nipah Virus by Reverse Vaccinology Approach. *Combinatorial chemistry &*
1667 *high throughput screening*, 23(8), pp.788-796.
- 1668 33. Sakib, M.S., Islam, M., Hasan, A.K.M. and Nabi, A.H.M., 2014. Prediction of
1669 epitope-based peptides for the utility of vaccine development from fusion
1670 and glycoprotein of nipah virus using in silico approach. *Advances in*
1671 *bioinformatics*, 2014.
- 1672 34. Eshaghi, M., Tan, W.S. and Yusoff, K., 2005. Identification of epitopes in the
1673 nucleocapsid protein of Nipah virus using a linear phage-displayed
1674 random peptide library. *Journal of medical virology*, 75(1), pp.147-152.
- 1675 35. Mohammed, A.A., Shantier, S.W., Mustafa, M.I., Osman, H.K., Elmansi, H.E.,
1676 Osman, I.A.A., Mohammed, R.A., Abdelrhman, F.A., Elnnewery, M.E.,
1677 Yousif, E.M. and Mustafa, M.M., 2020. Epitope-based peptide vaccine
1678 against glycoprotein G of Nipah henipavirus using immunoinformatics
1679 approaches. *Journal of immunology research*, 2020.
- 1680 36. Gupta, A.K., Kumar, A., Rajput, A., Kaur, K., Dar, S.A., Thakur, A., Megha, K.
1681 and Kumar, M., 2020. NipahVR: a resource of multi-targeted putative
1682 therapeutics and epitopes for the Nipah virus. *Database*, 2020.
- 1683 37. Habib, P.T., 2021. Learning from COVID-19 Pandemic: In Silico Vaccine and
1684 Cloning Design Against Nipah Virus by Studying and Analyzing the Whole
1685 Nipah Virus Proteome.

- 1686 38. Singh, R.K., Dhama, K., Chakraborty, S., Tiwari, R., Natesan, S., Khandia,
1687 R., Munjal, A., Vora, K.S., Latheef, S.K., Karthik, K. and Singh Malik, Y.,
1688 2019. Nipah virus: epidemiology, pathology, immunobiology and advances
1689 in diagnosis, vaccine designing and control strategies—a comprehensive
1690 review. *Veterinary Quarterly*, 39(1), pp.26-55.
- 1691 39. Majee, P., Jain, N. and Kumar, A., 2021. Designing of a multi-epitope vaccine
1692 candidate against Nipah virus by in silico approach: a putative prophylactic
1693 solution for the deadly virus. *Journal of Biomolecular Structure and*
1694 *Dynamics*, 39(4), pp.1461-1480.
- 1695 40. Ojha, R., Pareek, A., Pandey, R.K., Prusty, D. and Prajapati, V.K., 2019.
1696 Strategic development of a next-generation multi-epitope vaccine to
1697 prevent Nipah virus zoonotic infection. *ACS omega*, 4(8), pp.13069-
1698 13079.
- 1699 41. Wilson, S.S., Wiens, M.E. and Smith, J.G., 2013. Antiviral mechanisms of
1700 human defensins. *Journal of molecular biology*, 425(24), pp.4965-4980.
- 1701 42. Duits, L.A., Nibbering, P.H., Strijen, E., Vos, J.B., Manneke-Lazeroms, S.P.,
1702 Sterkenburg, M.A. and Hiemstra, P.S., 2003. Rhinovirus increases human
1703 β -defensin-2 and-3 mRNA expression in cultured bronchial epithelial cells.
1704 *Pathogens and Disease*, 38(1), pp.59-64.
- 1705 43. Yang, D., Biragyn, A., Kwak, L.W. and Oppenheim, J.J., 2002. Mammalian
1706 defensins in immunity: more than just microbicidal. *Trends in immunology*,
1707 23(6), pp.291-296.
- 1708 44. Biragyn, A., Surenhu, M., Yang, D., Ruffini, P.A., Haines, B.A.,
1709 Klyushnenkova, E., Oppenheim, J.J. and Kwak, L.W., 2001. Mediators of
1710 innate immunity that target immature, but not mature, dendritic cells
1711 induce antitumor immunity when genetically fused with nonimmunogenic
1712 tumor antigens. *The Journal of Immunology*, 167(11), pp.6644-6653.
- 1713 45. Duits, L.A., Nibbering, P.H., van Strijen, E., Vos, J.B., Manneke-Lazeroms,
1714 S.P., van Sterkenburg, M.A. and Hiemstra, P.S., 2003. Rhinovirus
1715 increases human β -defensin-2 and-3 mRNA expression in cultured
1716 bronchial epithelial cells. *FEMS Immunology & Medical Microbiology*,
1717 38(1), pp.59-64.
- 1718 46. Kohlgraf, K.G., Pingel, L.C., Dietrich, D.E. and Brogden, K.A., 2010.
1719 Defensins as anti-inflammatory compounds and mucosal adjuvants.
1720 *Future microbiology*, 5(1), pp.99-113.
- 1721 47. Antoniou, A.N., Powis, S.J. and Elliott, T., 2003. Assembly and export of
1722 MHC class I peptide ligands. *Current opinion in immunology*, 15(1), pp.75-
1723 81.
- 1724 48. Oldham, M.L., Grigorieff, N. and Chen, J., 2016. Structure of the Transporter
1725 associated with antigen processing trapped by herpes simplex virus. *eLife*,
1726 5, p.e21829.
- 1727 49. Meena, S.R., Gangwar, S.P. and Saxena, A.K., 2012. Purification,
1728 crystallization and preliminary X-ray crystallographic analysis of the
1729 ATPase domain of human TAP in nucleotide-free and ADP-, vanadate-
1730 and azide-complexed forms. *Acta Crystallographica Section F: Structural*
1731 *Biology and Crystallization Communications*, 68(6), pp.655-658.

- 1732 50. Delneste, Y., Beauvillain, C. and Jeannin, P., 2007. Innate immunity:
1733 structure and function of TLRs. *Medecine sciences: M/S*, 23(1), pp.67-73.
- 1734 51. Totura, A.L., Whitmore, A., Agnihothram, S., Schäfer, A., Katze, M.G., Heise,
1735 M.T. and Baric, R.S., 2015. Toll-like receptor 3 signaling via TRIF
1736 contributes to a protective innate immune response to severe acute
1737 respiratory syndrome coronavirus infection. *MBio*, 6(3), pp.e00638-15.
- 1738 52. Shaw, M.L., Cardenas, W.B., Zamarin, D., Palese, P. and Basler, C.F.,
1739 2005. Nuclear localization of the Nipah virus W protein allows for inhibition
1740 of both virus-and toll-like receptor 3-triggered signaling pathways. *Journal*
1741 *of virology*, 79(10), pp.6078-6088.
- 1742 53. Seto, J., Qiao, L., Guenzel, C.A., Xiao, S., Shaw, M.L., Hayot, F. and
1743 Sealfon, S.C., 2010. Novel Nipah virus immune-antagonism strategy
1744 revealed by experimental and computational study. *Journal of virology*,
1745 84(21), pp.10965-10973.
- 1746 54. Farina, C., Krumbholz, M., Giese, T., Hartmann, G., Aloisi, F. and Meinl, E.,
1747 2005. Preferential expression and function of Toll-like receptor 3 in human
1748 astrocytes. *Journal of neuroimmunology*, 159(1-2), pp.12-19.
- 1749 55. Weingartl, H., Czub, S., Copps, J., Berhane, Y., Middleton, D., Marszal, P.,
1750 Gren, J., Smith, G., Ganske, S., Manning, L. and Czub, M., 2005. Invasion
1751 of the central nervous system in a porcine host by Nipah virus. *Journal of*
1752 *virology*, 79(12), pp.7528-7534.
- 1753 56. Arnold K, Bordoli L, Kopp J, and Schwede T (2006). The SWISS-MODEL
1754 Workspace: A web-based environment for protein structure homology
1755 modelling. *Bioinformatics.*,22,195-201.
- 1756 57. Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz MM, Kloetzel PM,
1757 Rammensee HG, Schild H, Holzhutter HG. 2005. Modeling the MHC class
1758 I pathway by combining predictions of proteasomal cleavage, TAP
1759 transport and MHC class I binding. *Cell Mol Life Sci* 62:1025-1037.
- 1760 58. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG. 2003. Identifying
1761 MHC class I epitopes by predicting the TAP transport efficiency of epitope
1762 precursors. *J Immunol*171:1741-1749.
- 1763 59. Hoof, I., Peters, B., Sidney, J., Pedersen, L.E., Sette, A., Lund, O., Buus, S.
1764 and Nielsen, M., 2009. NetMHCpan, a method for MHC class I binding
1765 prediction beyond humans. *Immunogenetics*, 61(1), p.1.
- 1766 60. Calis JJA, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A,
1767 Kesmir C, Peters B. 2013. Properties of MHC class I presented peptides
1768 that enhance immunogenicity. *PloS Comp. Biol.* 8(1):361.
- 1769 61. Wang, P., Sidney, J., Kim, Y., Sette, A., Lund, O., Nielsen, M. and Peters,
1770 B., 2010. Peptide binding predictions for HLA DR, DP and DQ molecules.
1771 *BMC bioinformatics*, 11(1), p.568.
- 1772 62. Sidney, J., Assarsson, E., Moore, C., Ngo, S., Pinilla, C., Sette, A. and
1773 Peters, B., 2008. Quantitative peptide binding motifs for 19 human and
1774 mouse MHC class I molecules derived using positional scanning
1775 combinatorial peptide libraries. *Immunome research*, 4(1), p.2.
- 1776 63. Nielsen, M., Lundegaard, C. and Lund, O., 2007. Prediction of MHC class II
1777 binding affinity using SMM-align, a novel stabilization matrix alignment

- method. BMC bioinformatics, 8(1), p.238.
64. Sturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., Braxenthaler, M., Gallazzi, F., Protti, M.P., Sinigaglia, F. and Hammer, J., 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature biotechnology, 17(6), p.555.
65. Bui H. H, Sidney J, Dinh K, Southwood S, Newman M. J, Sette A. 2006. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics 17:153.
66. Larsen JE, Lund O, Nielsen M. 2006. Improved method for predicting linear B-cell epitopes. Immunome Res 2:2.
67. Chou PY, Fasman GD. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 47:45-148.
68. Emini EA, Hughes JV, Perlow DS, Boger J. 1985. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55:836-839.
69. Karplus PA, Schulz GE. 1985. Prediction of chain flexibility in proteins. Naturwissenschaften 72:212-213.
70. Kolaskar AS, Tongaonkar PC. 1990. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276:172-174.
71. Parker JM, Guo D, Hodges RS. 1986. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25:5425-5432.
72. J. V. Kringelum, C. Lundegaard, O. Lund, M. Nielsen. 2012. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 8:(12):e1002829.
73. Ponomarenko JV, Bui H, Li W, Fusseder N, Bourne PE, Sette A, Peters B. 2008. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 9:514.
74. Bui HH, Sidney J, Li W, Fusseder N, Sette A. 2007. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 8:361.
75. Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., Kumar, R., Raghava, G.P. and Open Source Drug Discovery Consortium, 2013. In silico approach for predicting toxicity of peptides and proteins. PLoS One, 8(9), p.e73957.
76. Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Söding, J. and Thompson, J.D., and Higgins D.G., 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular systems biology, 7(1), p.539.
77. Benkert, P., Tosatto, S.C. and Schomburg, D., 2008. QMEAN: A comprehensive scoring function for model quality assessment. Proteins: Structure, Function, and Bioinformatics, 71(1), pp.261-277.

- 1824 78. Singh, S., Singh, H., Tuknait, A., Chaudhary, K., Singh, B., Kumaran, S. and
1825 Raghava, G.P.S. (2015) PEPstrMOD: structure prediction of peptides
1826 containing natural, non-natural and modified residues. *Biology Direct*
1827 10:73.
- 1828 79. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell,
1829 D.S. and Olson, A.J., 2009. AutoDock4 and AutoDockTools4: Automated
1830 docking with selective receptor flexibility. *Journal of computational*
1831 *chemistry*, 30(16), pp.2785-2791.
- 1832 80. O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of
1833 docking with a new scoring function, efficient optimization and
1834 multithreading, *Journal of Computational Chemistry* 31 (2010) 455-461
- 1835 81. Abraham, M. J., Murtola, T., Schulz, R., Paál, S., Smith, J. C., Hess, B.,
1836 Lindahl, E. GROMACS: High performance molecular simulations through
1837 multi-level parallelism from lap- tops to supercomputers. *SoftwareX* 1–
1838 2:19–25, 2015.
- 1839 82. Jorgensen, W.L., Maxwell, D.S. and Tirado-Rives, J., 1996. Development
1840 and testing of the OPLS all-atom force field on conformational energetics
1841 and properties of organic liquids. *Journal of the American Chemical*
1842 *Society*, 118(45), pp.11225-11236.
- 1843 83. Abele, R. and Tampé, R., 2004. The ABCs of immunology: structure and
1844 function of TAP, the transporter associated with antigen processing.
1845 *Physiology*, 19(4), pp.216-224.
- 1846 84. Hu W, Li F, Yang X, Li Z, Xia H, Li G, Wang Y, Zhang Z. A flexible peptide
1847 linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47)
1848 fusion protein. *J Biotechnol.* 2004;107:83–90.
- 1849 85. Hajighahramani, N., Nezafat, N., Eslami, M., Negahdaripour, M.,
1850 Rahmatabadi, S.S. and Ghasemi, Y., 2017. Immunoinformatics analysis
1851 and in silico designing of a novel multi-epitope peptide vaccine against
1852 *Staphylococcus aureus*. *Infection, Genetics and Evolution*, 48, pp.83-94.
- 1853 86. Chen, X., Zaro, J.L. and Shen, W.C., 2013. Fusion protein linkers: property,
1854 design and functionality. *Advanced drug delivery reviews*, 65(10),
1855 pp.1357-1369.
- 1856 87. Hoover, D.M., Rajashankar, K.R., Blumenthal, R., Puri, A., Oppenheim, J.J.,
1857 Chertov, O. and Lubkowski, J., 2000. The structure of human β -defensin-2
1858 shows evidence of higher order oligomerization. *Journal of Biological*
1859 *Chemistry*, 275(42), pp.32911-32918. PDB ID: 1FD3.
- 1860 88. Nagpal, G., Gupta, S., Chaudhary, K., Dhanda, S.K., Prakash, S. and
1861 Raghava, G.P., 2015. VaccineDA: Prediction, design and genome-wide
1862 screening of oligodeoxynucleotide-based vaccine adjuvants. *Scientific*
1863 *reports*, 5, p.12478.
- 1864 89. Dhanda, S. K., Vir, P. & Raghava, G. P. Designing of interferon-gamma
1865 inducing MHC class-II binders. *Biol. Direct.* 8, 30 (2013).
- 1866 90. Saha, S. & Raghava, G. AlgPred: prediction of allergenic proteins and
1867 mapping of IgE epitopes. *Nucleic. Acids. Res.* 34, W202–W209 (2006).
- 1868 91. Irini A Doytchinova and Darren R Flower. VaxiJen: a server for prediction of
1869 protective antigens, tumour antigens and subunit vaccines. *BMC*

- 1870 Bioinformatics. 2007 8:4.
- 1871 92. Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S.E., Wilkins, M.R., Appel,
1872 R.D. and Bairoch, A., 2005. Protein identification and analysis tools on the
1873 ExPASy server (pp. 571-607). Humana Press.
- 1874 93. Morten Källberg, Haipeng Wang, Sheng Wang, Jian Peng, Zhiyong Wang,
1875 Hui Lu, and Jinbo Xu. Template-based protein structure modeling using
1876 the RaptorX web server. Nature Protocols 7, 1511-1522, 2012.
- 1877 94. Ma, J., Wang, S., Zhao, F. and Xu, J., 2013. Protein threading using context-
1878 specific alignment potential. Bioinformatics, 29(13), pp.i257-i265.
- 1879 95. Wang, Z., Zhao, F., Peng, J. and Xu, J., 2010, December. Protein 8-class
1880 secondary structure prediction using conditional neural fields. In 2010
1881 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
1882 (pp. 109-114). IEEE.
- 1883 96. Wang, Z. and Xu, J., 2013. Predicting protein contact map using evolutionary
1884 and physical constraints by integer programming. Bioinformatics, 29(13),
1885 pp.i266-i273.
- 1886 97. Dong Xu and Yang Zhang. Improving the Physical Realism and Structural
1887 Accuracy of Protein Models by a Two-step Atomic-level Energy
1888 Minimization. Biophysical Journal, vol 101, 2525-2534 (2011).
- 1889 98. J. Ko, H. Park, L. Heo, and C. Seok, GalaxyWEB server for protein structure
1890 prediction and refinement, Nucleic Acids Res. 40 (W1), W294-W297
1891 (2012).
- 1892 99. Shin, W.H., Lee, G.R., Heo, L., Lee, H. and Seok, C., 2014. Prediction of
1893 protein structure and interaction by GALAXY protein modeling programs.
1894 Bio Design, 2(1), pp.1-11.
- 1895 100. Ramakrishnan, C. and Ramachandran, G.N., 1965. Stereochemical criteria
1896 for polypeptide and protein chain conformations: II. Allowed conformations
1897 for a pair of peptide units. Biophysical journal, 5(6), pp.909-933.
- 1898 101. S.C. Lovell, I.W. Davis, W.B. Arendall III, P.I.W. de Bakker, J.M. Word, M.G.
1899 Prisant, J.S. Richardson and D.C. Richardson (2002) Structure validation
1900 by C α geometry: ϕ , ψ and C β deviation. Proteins: Structure,
1901 Function & Genetics. 50: 437-450.
- 1902 102. Bell, J.K., Botos, I., Hall, P.R., Askins, J., Shiloach, J., Segal, D.M. and
1903 Davies, D.R., 2005. The molecular structure of the Toll-like receptor 3
1904 ligand-binding domain. Proceedings of the National Academy of Sciences
1905 of the United States of America, 102(31), pp.10976-10980.
- 1906 103. Duhovny D, Nussinov R, Wolfson HJ. Efficient Unbound Docking of Rigid
1907 Molecules. In Gusfield et al., Ed. Proceedings of the 2'nd Workshop on
1908 Algorithms in Bioinformatics(WABI) Rome, Italy, Lecture Notes in
1909 Computer Science 2452, pp. 185-200, Springer Verlag, 2002
- 1910 104. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and
1911 SymmDock: servers for rigid and symmetric docking. Nucl. Acids. Res. 33:
1912 W363-367, 2005.
- 1913 105. Nezafat, N., Eslami, M., Negahdaripour, M., Rahbar, M.R. and Ghasemi, Y.,
1914 2017. Designing an efficient multi-epitope oral vaccine against
1915 Helicobacter pylori using immunoinformatics and structural vaccinology

1916 approaches. *Molecular BioSystems*, 13(4), pp.699-713.
 1917 106. Morla, S., Makhija, A. & Kumar, S. Synonymous codon usage pattern in
 1918 glycoprotein gene of rabies virus. *Gene*. 584, 1–6 (2016).
 1919 107. Wu, X., Wu, S., Li, D., Zhang, J., Hou, L., Ma, J., Liu, W., Ren, D., Zhu, Y.
 1920 and He, F., 2010. Computational identification of rare codons of
 1921 *Escherichia coli* based on codon pairs preference. *Bmc Bioinformatics*,
 1922 11(1), p.61.
 1923
 1924

A. CTL epitopes

B. HTL epitopes

bioRxiv preprint doi: <https://doi.org/10.1101/2021.05.17.460735>; this version posted May 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

GIGDPVTCLKSGAICHVPVFCPRRYKQIGTCGLPGTKCCKKP

EAAAK

EAAAK

YQNTYNHTOWILOTLY

AQITAGVALY

DLALSKYLSDLLFVF

GGGGS

LALSKYLSDLLFVFG

FALSNGVLF

ALSKYLSDLLFVFGP

KYLSDLLFVF

LSKYLSDLLFVFGPN

MTIQAISQAF

SKYLSDLLFVFGPNL

AENPVFTVF

KYLSDLLFVFGPNLQ

AVYNNEFY

YLSDLLFVFGPNLQD

LAMDEGYFAY

ASFSWDTMIKFGDVL

TVYHCSAVY

FSWDTMIKFGDVLTV

NYMYLICYG

GVYNDAFLIDRINWI

YMIPRTMLEF

NDAFLIDRINWISAG

EIISDIGNY

DAFLIDRINWISAGV

TPFVDSRAY

AFLIDRINWISAGVF

YPALALNEF

FLIDRINWISAGVFL

LDPVVTDVVY*

IPREFMIYDDVFIDN

LVSDAKMLSY*

FMIYDDVFIDNTGRI

MPSDDFSNTF

LSSDQVAELAAAVQE

VSDAKMLSY*

SSDQVAELAAAVQET

AEFFSFFRTF

SDQVAELAAAVQETS

ETDDYNGIY

DQVAELAAAVQETSA

FPISRLFNMY

QVAELAAAVQETSAG

FPVMGNRIY

*NNGNVCLVSDAKMLS

IATVYTWAY

*NGNVCLVSDAKMLSY

IMKKSFKAY

*GNVCLVSDAKMLS

IPFLFLSAY

*NVCLVSDAKMLS

KWYECFLFWF

*VCLVSDAKMLS

KYYQIDQPFF

NIDNIHLLAEFFSFF

LETDDYNGIY

IDNIHLLAEFFSFFR

RLFNMYRSY

DNIHLLAEFFSFFRT

SQNLLVTSY

NIHLLAEFFSFFRTF

SYFGLVLVCF

IHLAEFFSFFRTFG

TSDLDFVIFY

LELASFLMDRRVILP

YPECNNILF

ELASFLMDRRVILPR

EAAAK

LASFLMDRRVILPRA

HHHHHH

ASFLMDRRVILPRAA

LDFVIFYASLTYLRR

FVIFYASLTYLRRGI

EAAAK

HHHHHH

GIINTLQKYYCRVRGGRCVLSCLPKKEEQIGKCSTRGRKCCRKK

β Defensin 2

C Protein

Fusion Protein

Glycoprotein

Matrix Protein

Nucleocapsid

Phosphoprotein

Polymerase

β Defensin 3

Overlapping regions of predicted B cell Bepired linear Epitope and epitopes predicted by other protein sequence and structure based methods		Overlapping regions of sequence based B cell linear epitope prediction					Overlapping regions of structure based B cell epitope prediction		
		Chou & Fasman Beta-Turn	Emini Surface Accessibility	Karplus & Schulz Flexibility	Kolaskar & Tongaonkar Antigenicity	Parker Hydrophilicity	DiscoTope: discontinuous epitopes	EllIPro	
								Linear	Discontinuous
Fusion Protein	215 GPNLQDPVSNSM 226	215-226		215-226	215-216	217-226			
Glycoprotein	271 WTPPNPNT 278	271-278	271-278	272-278		272-278			271-278
Glycoprotein	459 SWDTMI 464	459-460							463-464
Glycoprotein	529 NQTAE 533	529-532	529-533	529-533		529-533			
Matrix Protein	184 SGIYM 188	184-188		184-188		184-188			
Matrix Protein	330 SIPREFMIY 338	330-335		330-336		331-334	332-333	332-333	333-338
Matrix Protein	340 DVFIDNTGRI 349	341-349		340-349		340-344			340-349
Phosphoprotein	125 GYGFTSSPERGWSDYTSGA 143	125-143	130-136	128-143		127-143			
Phosphoprotein	163 IAVSKEDR 170	166-170	166-170	163-170	163-166	165-170			
Polymerase	346 NIDN 349	348-349							
Polymerase	364 GHPILE 369	364-367			365-369				366-369
Polymerase	1095 DKSFDEDLEL 1104	1096-1103	1096-1101	1095-1104		1096-1103			1095-1104
Polymerase	1108 LMDR 1111								1108-1111
Polymerase	1409 LRLETDDYNG 1418	1412-1418	1410-1416	1412-1418		1411-1418	1409-1417	1409-1417	
Polymerase	1982 GFPIS 1986	1982-1986		1982-1986	1982-1986				1182-1986
Polymerase	2004 PVYSNPD 2010	2004-2010	2006-2010	2007-2010	2004-2008	2007-2010			2004-2010

Clusters of overlapping CTL, HTL & B cell epitopes

Fusion Protein	<div><div><div>-----KYLSDLLFVF-----</div><div>-----YLSDLLFVF-----</div><div>-----KYLSDLLFVF-----</div><div>-----SKYLSDLLFVF-----</div><div>-----LSKYLSDLLFVF-----</div><div>-----ALSKYLSDLLFVF-----</div><div>-----LALSKYLSDLLFVF-----</div><div>-----DLALSKYLSDLLFVF-----</div></div><div>-----MTIQAISQAF-----</div><div>-----GPNLQDDPVNSM-----</div><div>199-236 LDLALSKYLSDLLFVF-----GPNLQDDPVNSM-----MTIQAISQAFG</div></div>
Glycoprotein	<div><div><div>-----TVYHCSAVY-----</div><div>-----AVYNNEFY--</div><div>-----WTPPNPNT-----</div><div>270-293 VWTPPNPNTVYHCSAVYNNEFYV</div></div><div><div>-----FSDWTMIKFGDVLTV--</div><div>-----ASFSWDTMIKFGDVL--</div><div>-----SWDTMI-----</div><div>454-474 YQASFSDWTMIKFGDVLTVNP</div></div><div><div>-----AENPVFTVF-----</div><div>-----FLIDRINWISAGVFL-----</div><div>-----AFLIDRINWISAGVF-----</div><div>-----DAFLIDRINWISAGV-----</div><div>-----NDAFLIDRINWISAG-----</div><div>-----GVYNDAFLIDRINWI-----</div><div>-----NQTA-----</div><div>505-541 EGVYNDAFLIDRINWISAGVFLDSNQTAENPVFTVFK</div></div></div>
Matrix Protein	<div><div><div>-----YMIPRTMLEF-----</div><div>-----SGIYM-----</div><div>183-197 DSGIYMIPRTMLEFR</div></div><div><div>-----FMIYDDVFIDNTGRI-----</div><div>-----IPREFMIYDDVFIDN-----</div><div>-----DVFIDNTGRI-----</div><div>330-350 SIPREFMIYDDVFIDNTGRIL</div></div></div>
Nucleocapsid	<div><div><div>-----QVAELAAAVQETSAG--</div><div>-----DQVAELAAAVQETSAG--</div><div>-----SDQVAELAAAVQETSAG--</div><div>-----SSDQVAELAAAVQETSAG--</div><div>-----LSSDQVAELAAAVQETSAG--</div><div>382-404 LGLSSDQVAELAAAVQETSAGRQ</div></div></div>
Phosphoprotein	<div><div><div>-----LVSDAKMLS-----</div><div>-----VSDAKMLS-----</div><div>-----VCLVSDAKMLS-----</div><div>-----NVCLVSDAKMLS-----</div><div>-----GNVCLVSDAKMLS-----</div><div>-----NGNVCLVSDAKMLS-----</div><div>-----NNGNVCLVSDAKMLS-----</div><div>-----IAVSKEDR-----</div></div><div><div>-----GYGFTSSPERGWSYDTSAG-----</div><div>123-172 CTGYGFTSSPERGWSYDTSAGANNVCLVSDAKMLS-----IAVSKEDRET</div></div></div>
Polymerase	<div><div><div>-----AEFFSFFRTF-----</div><div>-----IHLLAEFFSFFRTFG-----</div><div>-----NIHLLAEFFSFFRTF-----</div><div>-----DNIHLLAEFFSFFRT-----</div><div>-----IDNIHLLAEFFSFFR-----</div><div>-----NIDNIHLLAEFFSFF-----</div><div>-----NIDN-----</div><div>345-370 LNIDNIHLLAEFFSFFRTFGHPILEA</div></div><div><div>-----ASFLMDRRVILPRAA-----</div><div>-----LASFLMDRRVILPRA-----</div><div>-----ELASFLMDRRVILPRA-----</div><div>-----LELASFLMDRRVILPRA-----</div><div>-----LMDR-----</div><div>1093-1124 FHDKSFDEDELELASFLMDRRVILPRAAHEILD</div></div><div><div>-----ETDDYNGIY-----</div><div>-----LETDDYNGIY-----</div><div>-----LRLETDDYNGIY-----</div><div>1408-1422 RLRLETDDYNGIYHL</div></div></div>
Polymerase	<div><div><div>-----TSDLDEVIFY-----</div><div>-----FVIFYASLTYLRRGI-----</div><div>-----LDFVIFYASLTYLRR-----</div><div>1715-1736 NTSDDLDFVIFYASLTYLRRGII</div></div><div><div>-----SYFGLVLVCF-----</div><div>-----RLFNMYSY-----</div><div>-----FPISRLFNM-----</div><div>-----PVYSNPD-----</div><div>1981-2012 PGFPISRLFNMYSYFGLVLVCFPVYSNPDST</div></div></div>

A. CTL epitopes - HLA Class I allele complexes

B. HTL epitopes - HLA Class II allele complexes

A **B**

CTL multi-epitope vaccine:

HTL multi-epitope vaccine:

A

E

B

F

C

G

D

Atom

H

Atom

A. B-factor of CTL epitope & HLA I allele complexes

B. B-factor of HTL epitope & HLA II allele complexes